BRCA1 O
is O
secreted O
and O
exhibits O
properties O
of O
a O
granin O
. O

However O
, O
the O
function O
of O
the O
BRCA1 O
protein O
has O
remained O
elusive O
. O

We O
now O
show O
that O
BRCA1 O
encodes O
a O
190 O
- O
kD O
protein O
with O
sequence O
homology O
and O
biochemical O
analogy O
to O
the O
granin O
protein O
family O
. O

Interestingly O
, O
BRCA2 O
also O
includes O
a O
motif O
similar O
to O
the O
granin O
consensus O
at O
the O
C O
terminus O
of O
the O
protein O
. O

Both O
BRCA1 O
and O
the O
granins O
localize O
to O
secretory O
vesicles O
, O
are O
secreted O
by O
a O
regulated O
pathway O
, O
are O
post O
- O
translationally O
glycosylated O
and O
are O
responsive O
to O
hormones O
. O

As O
a O
regulated O
secretory O
protein O
, O
BRCA1 O
appears O
to O
function O
by O
a O
mechanism O
not O
previously O
described O
for O
tumour B
suppressor O
gene O
products O
. O
. O

Women O
who O
carry O
a O
mutation O
in O
the O
BRCA1 O
gene O
( O
on O
chromosome O
17q21 O
) O
, O
have O
an O
80 O
% O
risk O
of O
breast B
cancer I
and O
a O
40 O
% O
risk O
of O
ovarian B
cancer I
by O
the O
age O
of O
70 O
( O
ref O
. O
1 O
) O
. O

The O
variable O
penetrance O
of O
BRCA1 O
suggests O
that O
other O
genetic O
and O
non O
- O
genetic O
factors O
play O
a O
role O
in O
tumourigenesis B
in O
these O
individuals O
. O

The O
HRAS1 O
variable O
number O
of O
tandem O
repeats O
( O
VNTR O
) O
polymorphism O
, O
located O
1 O
kilobase O
( O
kb O
) O
downstream O
of O
the O
HRAS1 O
proto O
- O
oncogene O
( O
chromosome O
11p15 O
. O
5 O
) O
is O
one O
possible O
genetic O
modifier O
of O
cancer B
penetrance O
. O

Individuals O
who O
have O
rare O
alleles O
of O
the O
VNTR O
have O
an O
increased O
risk O
of O
certain O
types O
of O
cancers B
, O
including O
breast B
cancer I
( O
2 O
- O
4 O
) O
. O

The O
risk O
for O
ovarian B
cancer I
was O
2 O
. O

11 O
times O
greater O
for O
BRCA1 O
carriers O
harbouring O
one O
or O
two O
rare O
HRAS1 O
alleles O
, O
compared O
to O
carriers O
with O
only O
common O
alleles O
( O
P O
= O
0 O
. O
015 O
) O
. O

Susceptibility O
to O
breast B
cancer I
did O
not O
appear O
to O
be O
affected O
by O
the O
presence O
of O
rare O
HRAS1 O
alleles O
. O

3 O
. O

Characterisation O
of O
the O
expression O
of O
this O
gene O
in O
patient O
tissues O
has O
thus O
far O
generated O
conflicting O
data O
on O
alterations O
in O
the O
steady O
state O
levels O
of O
DMPK O
mRNA O
, O
and O
on O
the O
final O
DMPK O
protein O
levels O
in O
the O
presence O
of O
the O
expansion O
. O

We O
have O
searched O
for O
genes O
associated O
with O
a O
CpG O
island O
at O
the O
3 O
end O
of O
DMPK O
. O

Sequencing O
of O
this O
region O
shows O
that O
the O
island O
extends O
over O
3 O
. O

5 O
kb O
and O
is O
interrupted O
by O
the O
( O
CTG O
) O
n O
repeat O
. O

Comparison O
of O
genomic O
sequences O
downstream O
( O
centromeric O
) O
of O
the O
repeat O
in O
human O
and O
mouse O
identified O
regions O
of O
significant O
homology O
. O

These O
correspond O
to O
exons O
of O
a O
gene O
predicted O
to O
encode O
a O
homeodomain O
protein O
. O

For O
improvement O
over O
previous O
studies O
, O
a O
new O
set O
of O
primers O
has O
been O
designed O
, O
which O
allow O
for O
amplification O
of O
the O
coding O
and O
splicing O
sequences O
only O
. O

The O
positioning O
of O
the O
polymerase O
chain O
reaction O
( O
PCR O
) O
primers O
was O
such O
that O
the O
resulting O
PCR O
products O
were O
of O
different O
sizes O
, O
which O
enabled O
us O
to O
analyze O
two O
different O
exons O
simultaneously O
and O
still O
distinguish O
between O
the O
banding O
profiles O
for O
both O
( O
biplex O
analysis O
) O
. O

By O
using O
this O
approach O
, O
we O
were O
able O
to O
identify O
mutation O
in O
22 O
new O
patients O
, O
but O
the O
overall O
efficiency O
of O
the O
procedure O
when O
we O
used O
a O
single O
- O
pass O
regimen O
was O
only O
48 O
% O
. O

The O
mutations O
were O
small O
insertions O
and O
deletions O
and O
point O
mutations O
in O
roughly O
equal O
proportions O
. O
. O

Allele O
- O
specific O
amino O
acid O
substitutions O
( O
Ser189 O
- O
- O
> O
Phe O
; O
Gly444 O
- O
- O
> O
Arg O
) O
cause O
impaired O
C2 O
secretion O
. O

One O
is O
in O
exon O
5 O
( O
nucleotide O
C566 O
- O
- O
> O
T O
; O
Ser189 O
- O
- O
> O
Phe O
) O
of O
the O
C2Q0 O
gene O
linked O
to O
the O
MHC O
haplotype O
A11 O
, O
B35 O
, O
DRw1 O
, O
BFS O
, O
C4A0B1 O
. O

The O
other O
is O
in O
exon O
11 O
( O
G1930 O
- O
- O
> O
A O
; O
Gly444 O
- O
- O
> O
Arg O
) O
of O
the O
C2Q0 O
gene O
linked O
to O
the O
MHC O
haplotype O
A2 O
, O
B5 O
, O
DRw4 O
, O
BFS O
, O
C4A3B1 O
. O

Each O
mutant O
C2 O
gene O
product O
is O
retained O
early O
in O
the O
secretory O
pathway O
. O

These O
mutants O
provide O
models O
for O
elucidating O
the O
C2 O
secretory O
pathway O
. O
. O

In O
one O
family O
, O
both O
alleles O
were O
normal O
in O
the O
parents O
and O
one O
sister O
; O
thus O
, O
the O
mutation O
originated O
de O
novo O
in O
the O
proposita O
. O

The O
second O
patient O
also O
had O
asymptomatic O
parents O
who O
, O
however O
, O
were O
not O
available O
for O
study O
. O

The O
structural O
consequences O
of O
the O
identified O
mutation O
, O
resulting O
in O
the O
CyS2010 O
- O
> O
Arg O
substitution O
, O
were O
evaluated O
by O
expression O
of O
the O
vWF O
carboxyl O
- O
terminal O
domain O
containing O
residues O
1366 O
- O
2050 O
. O

Insect O
cells O
infected O
with O
recombinant O
baculovirus O
expressing O
normal O
vWF O
sequence O
secreted O
a O
disulfide O
linked O
dimeric O
molecule O
with O
an O
apparent O
molecular O
mass O
of O
150 O
kDa O
before O
reduction O
, O
yielding O
a O
single O
band O
of O
80 O
kDa O
after O
disulfide O
bond O
reduction O
. O

In O
contrast O
, O
cells O
expressing O
the O
mutant O
fragment O
secreted O
a O
monomeric O
molecule O
of O
apparent O
molecular O
mass O
of O
80 O
kDa O
, O
which O
remained O
unchanged O
after O
reduction O
. O

The O
Rho O
family O
of O
GTPases O
control O
diverse O
biological O
processes O
, O
including O
cell O
morphology O
and O
mitogenesis O
. O

This O
interaction O
is O
dependent O
on O
the O
presence O
of O
the O
G O
protein O
- O
binding O
domain O
. O

Cellular O
expression O
of O
epitope O
- O
tagged O
WASP O
produces O
clusters O
of O
WASP O
that O
are O
highly O
enriched O
in O
polymerized O
actin O
. O

This O
clustering O
is O
not O
observed O
with O
a O
C O
- O
terminally O
deleted O
WASP O
and O
is O
inhibited O
by O
coexpression O
with O
dominant O
negative O
CDC42Hs O
- O
N17 O
, O
but O
not O
with O
dominant O
negative O
forms O
of O
Rac O
or O
Rho O
. O

The O
WASP O
sequence O
contains O
two O
novel O
domains O
that O
are O
homologous O
to O
other O
proteins O
involved O
in O
action O
organization O
. O
. O

In O
5 O
of O
14 O
patients O
( O
35 O
% O
) O
, O
elevated O
plasma O
concentrations O
of O
very O
long O
chain O
fatty O
acids O
were O
detected O
. O

None O
of O
these O
patients O
had O
adrenocortical O
antibodies O
. O

Tumor B
suppression O
and O
apoptosis O
of O
human O
prostate B
carcinoma I
mediated O
by O
a O
genetic O
locus O
within O
human O
chromosome O
10pter O
- O
q11 O
. O

Yet O
, O
despite O
a O
large O
international O
effort O
, O
little O
is O
known O
about O
the O
molecular O
mechanisms O
that O
underlie O
this O
devastating O
disease O
. O

Prostate O
secretory O
epithelial O
cells O
and O
androgen O
- O
dependent O
prostate B
carcinomas I
undergo O
apoptosis O
in O
response O
to O
androgen O
deprivation O
and O
, O
furthermore O
, O
most O
prostate B
carcinomas I
become O
androgen O
independent O
and O
refractory O
to O
further O
therapeutic O
manipulations O
during O
disease O
progression O
. O

Definition O
of O
the O
genetic O
events O
that O
trigger O
apoptosis O
in O
the O
prostate O
could O
provide O
important O
insights O
into O
critical O
pathways O
in O
normal O
development O
as O
well O
as O
elucidate O
the O
perturbations O
of O
those O
key O
pathways O
in O
neoplastic B
transformation O
. O

We O
report O
the O
functional O
definition O
of O
a O
novel O
genetic O
locus O
within O
human O
chromosome O
10pter O
- O
q11 O
that O
mediates O
both O
in O
vivo O
tumor B
suppression O
and O
in O
vitro O
apoptosis O
of O
prostatic B
adenocarcinoma I
cells O
. O

A O
defined O
fragment O
of O
human O
chromosome O
10 O
was O
transferred O
via O
microcell O
fusion O
into O
a O
prostate B
adenocarcinoma I
cell O
line O
. O

Microcell O
hybrids O
containing O
only O
the O
region O
10pter O
- O
q11 O
were O
suppressed O
for O
tumorigenicity B
following O
injection O
of O
microcell O
hybrids O
into O
nude O
mice O
. O

Furthermore O
, O
the O
complemented O
hybrids O
undergo O
programmed O
cell O
death I
in O
vitro O
via O
a O
mechanism O
that O
does O
not O
require O
nuclear O
localization O
of O
p53 O
. O

These O
data O
functionally O
define O
a O
novel O
genetic O
locus O
, O
designated O
PAC1 O
, O
for O
prostate B
adenocarcinoma I
1 O
, O
involved O
in O
tumor B
suppression O
of O
human O
prostate B
carcinoma I
and O
furthermore O
strongly O
suggest O
that O
the O
cell O
death O
pathway O
can O
be O
functionally O
restored O
in O
prostatic B
adenocarcinoma I
. O
. O

Low O
incidence O
of O
BRCA2 O
mutations O
in O
breast B
carcinoma I
and O
other O
cancers B
. O

Inherited O
mutant O
alleles O
of O
familial O
tumour B
suppressor O
genes O
predispose O
individuals O
to O
particular O
types O
of O
cancer B
. O

This O
finding O
suggests O
that O
other O
genes O
may O
be O
the O
principal O
targets O
for O
somatic O
mutation O
in O
breast B
carcinoma I
. O

Like O
BRCA1 O
, O
BRCA2 O
behaves O
as O
a O
dominantly O
inherited O
tumour B
suppressor O
gene O
. O

The O
BRCA2 O
coding O
sequence O
is O
huge O
, O
composed O
of O
26 O
exons O
that O
span O
10 O
, O
443 O
bp O
. O

Surprisingly O
, O
mutations O
in O
BRCA2 O
are O
infrequent O
in O
cancers B
including O
breast B
carcinoma I
. O

Nine O
different O
germ O
- O
line O
mutations O
in O
the O
BRCA1 O
breast B
and I
ovarian I
cancer I
susceptibility O
gene O
were O
identified O
in O
15 O
of O
47 O
kindreds O
from O
southern O
Sweden O
, O
by O
use O
of O
SSCP O
and O
heteroduplex O
analysis O
of O
all O
exons O
and O
flanking O
intron O
region O
and O
by O
a O
protein O
- O
truncation O
test O
for O
exon O
11 O
, O
followed O
by O
direct O
sequencing O
. O

All O
but O
one O
of O
the O
mutations O
are O
predicted O
to O
give O
rise O
to O
premature O
translation O
termination O
and O
include O
seven O
frameshift O
insertions O
or O
deletions O
, O
a O
nonsense O
mutation O
, O
and O
a O
splice O
acceptor O
site O
mutation O
. O

The O
remaining O
mutation O
is O
a O
missense O
mutation O
( O
Cys61Gly O
) O
in O
the O
zinc O
- O
binding O
motif O
. O

Four O
novel O
Swedish O
founding O
mutations O
were O
identified O
the O
nucleotide O
2595 O
deletion O
A O
was O
found O
in O
five O
families O
, O
the O
C O
1806 O
T O
nonsense O
mutation O
in O
three O
families O
, O
the O
3166 O
insertion O
TGAGA O
in O
three O
families O
, O
and O
the O
nucleotide O
1201 O
deletion O
11 O
in O
two O
families O
. O

Analysis O
of O
the O
intragenic O
polymorphism O
D17S855 O
supports O
common O
origins O
of O
the O
mutations O
. O

Eleven O
of O
the O
15 O
kindreds O
manifesting O
BRCA1 O
mutations O
were O
breast B
- I
ovarian I
cancer I
families O
, O
several O
of O
them O
with O
a O
predominant O
ovarian B
cancer I
phenotype O
. O

The O
set O
of O
32 O
families O
in O
which O
no O
BRCA1 O
alterations O
were O
detected O
included O
1 O
breast B
- I
ovarian I
cancer I
kindred O
manifesting O
clear O
linkage O
to O
the O
BRCA1 O
region O
and O
loss O
of O
the O
wild O
- O
type O
chromosome O
in O
associated O
tumors B
. O

In O
all O
, O
12 O
of O
16 O
kindreds O
manifesting O
BRCA1 O
mutation O
or O
linkage O
contained O
ovarian B
cancer I
, O
as O
compared O
with O
only O
6 O
of O
the O
remaining O
31 O
families O
( O
P O
< O
. O
001 O
) O
. O

Rapid O
detection O
of O
regionally O
clustered O
germ O
- O
line O
BRCA1 O
mutations O
by O
multiplex O
heteroduplex O
analysis O
. O

Germ O
- O
line O
mutations O
of O
the O
BRCA1 O
gene O
are O
responsible O
for O
a O
substantial O
proportion O
of O
families O
with O
multiple O
cases O
of O
early O
- O
onset O
breast B
and I
/ I
or I
ovarian I
cancer I
. O

Since O
the O
isolation O
of O
BRCA1 O
last O
year O
, O
> O
65 O
distinct O
mutations O
scattered O
throughout O
the O
coding O
region O
have O
been O
detected O
, O
making O
analysis O
of O
the O
gene O
time O
consuming O
and O
technically O
challenging O
. O

We O
have O
developed O
a O
multiplex O
heteroduplex O
analysis O
that O
is O
designed O
to O
analyze O
one O
- O
quarter O
of O
the O
coding O
sequence O
in O
a O
single O
- O
step O
screening O
procedure O
and O
that O
will O
detect O
approximately O
50 O
% O
of O
all O
BRCA1 O
mutations O
so O
far O
reported O
in O
breast B
/ I
ovarian I
cancer I
families O
. O

We O
have O
used O
this O
technique O
to O
analyze O
BRCA1 O
in O
162 O
families O
with O
a O
history O
of O
breast B
and I
/ I
or I
ovarian I
cancer I
and O
identified O
12 O
distinct O
mutations O
in O
35 O
families O
. O
. O

Codon O
344 O
is O
a O
key O
residue O
within O
the O
tetramerisation O
domain O
, O
and O
the O
amino O
acid O
substitution O
of O
a O
proline O
for O
a O
leucine O
is O
predicted O
to O
have O
profound O
implications O
for O
tetramerisation O
and O
potentially O
DNA O
binding O
. O

A O
cell O
line O
has O
been O
established O
from O
the O
tumour B
of O
the O
proband O
and O
cytogenetic O
and O
molecular O
studies O
carried O
out O
, O
providing O
an O
extensive O
analysis O
in O
this O
family O
. O
. O

Previous O
investigations O
by O
Southern O
blot O
hybridization O
and O
PCR O
fragment O
- O
length O
analysis O
had O
revealed O
mutations O
in O
48 O
patients O
. O

Here O
we O
report O
on O
the O
analysis O
of O
the O
remaining O
71 O
patients O
. O

By O
applying O
heteroduplex O
analysis O
, O
nonisotopic O
SSCP O
, O
and O
direct O
sequencing O
, O
we O
detected O
germ O
- O
line O
mutations O
resulting O
in O
premature O
termination O
codons O
or O
disruption O
of O
splice O
signals O
in O
51 O
( O
72 O
% O
) O
of O
the O
71 O
patients O
. O

Four O
patients O
also O
showed O
rare O
sequence O
variants O
. O

No O
region O
of O
the O
RB1 O
gene O
was O
preferentially O
involved O
in O
single O
base O
substitutions O
. O

Recurrent O
transitions O
were O
observed O
at O
most O
of O
the O
14 O
codons O
within O
the O
RB1 O
. O

No O
mutation O
was O
observed O
in O
exons O
25 O
- O
27 O
, O
although O
this O
region O
contains O
two O
CGA O
codons O
. O

This O
suggests O
that O
mutations O
within O
the O
3 O
- O
terminal O
region O
of O
the O
RB1 O
gene O
may O
not O
be O
oncogenic O
. O

When O
these O
data O
were O
combined O
with O
the O
results O
of O
our O
previous O
investigations O
, O
mutations O
were O
identified O
in O
a O
total O
of O
99 O
( O
83 O
% O
) O
of O
119 O
patients O
. O

The O
spectrum O
comprises O
15 O
% O
large O
deletions O
, O
26 O
% O
small O
length O
alterations O
, O
and O
42 O
% O
base O
substitutions O
. O

Most O
large O
analyses O
that O
defined O
the O
limits O
of O
the O
normal O
and O
pathological O
size O
ranges O
employed O
PCR O
assays O
, O
which O
included O
the O
CAG O
repeats O
and O
a O
CCG O
repeat O
tract O
that O
was O
thought O
to O
be O
invariant O
. O

Many O
of O
these O
experiments O
found O
an O
overlap O
between O
the O
normal O
and O
disease O
size O
ranges O
. O

Subsequent O
findings O
that O
the O
CCG O
repeats O
vary O
by O
8 O
trinucleotide O
lengths O
suggested O
that O
the O
limits O
of O
the O
normal O
and O
disease O
size O
ranges O
should O
be O
reevaluated O
with O
assays O
that O
exclude O
the O
CCG O
polymorphism O
. O

Since O
patients O
with O
between O
30 O
and O
40 O
repeats O
are O
rare O
, O
a O
consortium O
was O
assembled O
to O
collect O
such O
individuals O
. O

All O
178 O
samples O
were O
reanalyzed O
in O
Cambridge O
by O
using O
assays O
specific O
for O
the O
CAG O
repeats O
. O

We O
have O
optimized O
methods O
for O
reliable O
sizing O
of O
CAG O
repeats O
and O
show O
cases O
that O
demonstrate O
the O
dangers O
of O
using O
PCR O
assays O
that O
include O
both O
the O
CAG O
and O
CCG O
polymorphisms O
. O

Mutations O
in O
ASPA O
that O
lead O
to O
loss O
of O
enzymatic O
activity O
have O
been O
identified O
, O
and O
E285A O
and O
Y231X O
are O
the O
two O
predominant O
mutations O
that O
account O
for O
97 O
% O
of O
the O
mutant O
chromosomes O
in O
Ashkenazi O
Jewish O
patients O
. O

Eight O
novel O
and O
three O
previously O
characterized O
mutations O
accounted O
for O
80 O
% O
( O
40 O
/ O
50 O
) O
of O
mutant O
chromosomes O
. O

The O
A305E O
missense O
mutation O
accounted O
for O
48 O
% O
( O
24 O
/ O
50 O
) O
of O
mutant O
chromosomes O
in O
patients O
of O
western O
European O
descent O
, O
while O
the O
two O
predominant O
Jewish O
mutations O
each O
accounted O
for O
a O
single O
mutant O
chromosome O
. O

The O
eight O
novel O
mutations O
identified O
included O
1 O
- O
and O
4 O
- O
bp O
deletions O
( O
32 O
deltaT O
and O
876 O
deltaAGAA O
, O
respectively O
) O
and O
I16T O
, O
G27R O
, O
D114E O
, O
G123E O
, O
C152Y O
, O
and O
R168C O
missense O
mutations O
. O

The O
heterozygosity O
for O
876 O
deltaAGAA O
mutation O
was O
identified O
in O
three O
independent O
patients O
from O
England O
. O

Six O
single O
- O
base O
changes O
leading O
to O
missense O
mutations O
were O
identified O
in O
patients O
from O
Turkey O
( O
D114E O
, O
R168C O
) O
, O
The O
Netherlands O
( O
I16T O
) O
, O
Germany O
( O
G27R O
) O
, O
Ireland O
( O
C152Y O
) O
, O
and O
Canada O
( O
G123E O
) O
. O

A O
PCR O
- O
based O
protocol O
is O
described O
that O
was O
used O
to O
introduce O
mutations O
in O
wild O
- O
type O
cDNA O
. O

The O
entire O
coding O
sequence O
of O
the O
Atm O
transcript O
was O
cloned O
and O
found O
to O
contain O
an O
open O
reading O
frame O
encoding O
a O
protein O
of O
3066 O
amino O
acids O
with O
84 O
% O
overall O
identity O
and O
91 O
% O
similarity O
to O
the O
human O
ATM O
protein O
. O

Variable O
levels O
of O
expression O
of O
Atm O
were O
observed O
in O
different O
tissues O
. O

Fluorescence O
in O
situ O
hybridization O
and O
linkage O
analysis O
located O
the O
Atm O
gene O
on O
mouse O
chromosome O
9 O
, O
band O
9C O
, O
in O
a O
region O
homologous O
to O
the O
ATM O
region O
on O
human O
chromosome O
11q22 O
- O
q23 O
. O
. O

A O
distinct O
feature O
of O
the O
mouse O
gene O
is O
an O
expanded O
polymorphic O
GGA O
trinucleotide O
repeat O
that O
codes O
for O
polyglycine O
and O
varies O
from O
15 O
to O
17 O
triplets O
in O
different O
Mus O
musculus O
strains O
. O

The O
genomic O
structure O
of O
the O
mouse O
WASP O
gene O
is O
expressed O
as O
an O
approximately O
2 O
. O

4 O
- O
kb O
mRNA O
in O
thymus O
and O
spleen O
. O

Chromosomal O
mapping O
in O
an O
interspecific O
M O
. O

Musculus O
/ O
M O
. O
spretus O
backcross O
placed O
the O
Wasp O
locus O
near O
the O
centromere O
of O
the O
mouse O
X O
chromosome O
, O
inseparable O
from O
Gata1 O
, O
Tcfe3 O
, O
and O
scurfy O
( O
sf O
) O
. O

Northern O
analysis O
of O
sf O
tissue O
samples O
indicated O
the O
presence O
of O
WASP O
mRNA O
in O
liver O
and O
skin O
, O
presumably O
as O
a O
consequence O
of O
lymphocytic O
infiltration O
, O
but O
non O
abnormalities O
in O
the O
amount O
or O
size O
of O
mRNA O
present O
. O

OBJECTIVE O
. O

METHODS O
. O

Using O
a O
specific O
radioimmunoassay O
, O
we O
determined O
colchicine O
concentrations O
in O
the O
serum O
and O
breast O
milk O
of O
4 O
patients O
at O
various O
time O
points O
, O
following O
oral O
administration O
of O
the O
drug O
. O

RESULTS O
. O

Colchicine O
was O
found O
to O
be O
excreted O
in O
breast O
milk O
. O

Its O
levels O
ranged O
between O
1 O
. O

9 O
and O
8 O
. O

6 O
ng O
/ O
ml O
, O
which O
were O
similar O
to O
those O
found O
in O
the O
serum O
( O
parallel O
concentration O
time O
curves O
) O
. O

However O
, O
there O
appeared O
to O
be O
a O
considerable O
variation O
in O
colchicine O
milk O
concentration O
among O
the O
different O
patients O
, O
which O
might O
be O
related O
to O
individual O
breast O
milk O
composition O
and O
, O
possibly O
, O
to O
other O
nutritional O
or O
metabolic O
factors O
. O

CONCLUSION O
. O

The O
extensive O
peripheral O
tissue O
binding O
and O
relatively O
low O
concentration O
of O
colchicine O
in O
breast O
milk O
suggests O
that O
the O
amount O
ingested O
by O
the O
infant O
is O
small O
. O

The O
effect O
of O
altered O
expression O
levels O
of O
DMPK O
, O
which O
is O
ubiquitously O
expressed O
in O
all O
muscle O
cell O
lineages O
during O
development O
, O
was O
examined O
by O
disrupting O
the O
endogenous O
Dmpk O
gene O
and O
overexpressing O
a O
normal O
human O
DMPK O
transgene O
in O
mice O
. O

These O
results O
strengthen O
the O
contention O
that O
simple O
loss O
- O
or O
gain O
- O
of O
- O
expression O
of O
DMPK O
is O
not O
the O
only O
crucial O
requirement O
for O
development O
of O
the O
disease O
. O
. O

Adult O
Dmpk O
- O
/ O
- O
mice O
show O
ultrastructural O
changes O
in O
muscle O
and O
a O
50 O
% O
decrease O
in O
force O
generation O
compared O
to O
young O
mice O
. O

The O
tumor O
suppressor O
gene O
Brca1 O
is O
required O
for O
embryonic O
cellular O
proliferation O
in O
the O
mouse O
. O

Mutations O
of O
the O
BRCA1 O
gone O
in O
humans O
are O
associated O
with O
predisposition O
to O
breast B
and I
ovarian I
cancers I
. O

We O
show O
here O
that O
Brca1 O
+ O
/ O
- O
mice O
are O
normal O
and O
fertile O
and O
lack O
tumors B
by O
age O
eleven O
months O
. O

Homozygous O
Brca1 O
( O
5 O
- O
6 O
) O
mutant O
mice O
die O
before O
day O
7 O
. O

5 O
of O
embryogenesis O
. O

Mutant O
embryos O
are O
poorly O
developed O
, O
with O
no O
evidence O
of O
mesoderm O
formation O
. O

The O
extraembryonic O
region O
is O
abnormal O
, O
but O
aggregation O
with O
wild O
- O
type O
tetraploid O
embryos O
does O
not O
rescue O
the O
lethality O
. O

In O
vivo O
, O
mutant O
embryos O
do O
not O
exhibit O
increased O
apoptosis O
but O
show O
reduced O
cell O
proliferation O
accompanied O
by O
decreased O
expression O
of O
cyclin O
E O
and O
mdm O
- O
2 O
, O
a O
regulator O
of O
p53 O
activity O
. O

The O
expression O
of O
cyclin O
- O
dependent O
kinase O
inhibitor O
p21 O
is O
dramatically O
increased O
in O
the O
mutant O
embryos O
. O

Buttressing O
these O
in O
vivo O
observations O
is O
the O
fact O
that O
mutant O
blastocyst O
growth O
is O
grossly O
impaired O
in O
vitro O
. O

Thus O
, O
the O
death O
of O
Brca1 O
( O
5 O
- O
6 O
) O
mutant O
embryos O
prior O
to O
gastrulation O
may O
be O
due O
to O
a O
failure O
of O
the O
proliferative O
burst O
required O
for O
the O
development O
of O
the O
different O
germ O
layers O
. O

Increased O
coronary B
heart I
disease I
in O
Japanese O
- O
American O
men O
with O
mutation O
in O
the O
cholesteryl O
ester O
transfer O
protein O
gene O
despite O
increased O
HDL O
levels O
. O

The O
cholesteryl O
ester O
transfer O
protein O
( O
CETP O
) O
mediates O
the O
transfer O
of O
cholesteryl O
esters O
from O
HDL O
to O
other O
lipoproteins O
and O
is O
a O
key O
participant O
in O
the O
reverse O
transport O
of O
cholesterol O
from O
the O
periphery O
to O
the O
liver O
. O

A O
high O
prevalence O
of O
two O
different O
CETP O
gene O
mutations O
( O
D442G O
, O
5 O
. O
1 O
% O
; O
intron O
14G O
A O
, O
0 O
. O
5 O
% O
) O
, O
was O
found O
in O
3 O
, O
469 O
men O
of O
Japanese O
ancestry O
in O
the O
Honolulu O
Heart O
Program O
and O
mutations O
were O
associated O
with O
decreased O
CETP O
( O
- O
35 O
% O
) O
and O
increased O
HDL O
chol O
levels O
( O
+ O
10 O
% O
for O
D442G O
) O
. O

55 O
( O
P O
= O
. O
02 O
) O
; O
after O
additional O
adjustment O
for O
HDL O
levels O
, O
the O
RR O
was O
1 O
. O

68 O
( O
P O
= O
. O
008 O
) O
. O

Similar O
RR O
values O
were O
obtained O
for O
the O
D442G O
mutation O
alone O
. O

The O
findings O
suggest O
that O
both O
HDL O
concentration O
and O
the O
dynamics O
of O
cholesterol O
transport O
through O
HDL O
( O
i O
. O
e O
. O
, O
reverse O
cholesterol O
transport O
) O
determine O
the O
anti O
- O
atherogenicity B
of O
the O
HDL O
fraction O
. O

Mapping O
the O
homolog O
of O
the O
human O
Rb1 O
gene O
to O
chromosome O
14 O
of O
higher O
primates O
. O

2 O
2 O
. O

A O
unique O
sequence O
human O
Rb1 O
cosmid O
DNA O
probe O
has O
been O
used O
to O
localize O
this O
region O
on O
apes O
Chr O
14 O
by O
the O
FISH O
technique O
. O

The O
conservation O
of O
the O
Rb1 O
gene O
in O
higher O
primates O
at O
the O
corresponding O
equivalent O
chromosome O
locus O
( O
14q14 O
) O
of O
the O
human O
may O
serve O
as O
a O
phylogenetic O
marker O
to O
further O
trace O
the O
evolutionary O
pathway O
of O
human O
descent O
. O

Mutation O
analysis O
in O
19 O
families O
of O
German O
, O
Swiss O
and O
Turkish O
descent O
by O
single O
- O
strand O
conformation O
polymorphism O
and O
sequencing O
resulted O
in O
the O
detection O
of O
seven O
novel O
and O
10 O
known O
mutations O
. O

A O
striking O
clustering O
of O
missense O
mutations O
in O
the O
first O
four O
exons O
contrasted O
with O
a O
random O
distribution O
of O
nonsense O
mutations O
. O

More O
than O
85 O
% O
of O
all O
known O
missense O
mutations O
were O
localized O
in O
the O
amino O
- O
terminal O
stretch O
of O
the O
WASP O
gene O
product O
; O
this O
region O
contained O
a O
mutational O
hot O
spot O
at O
codon O
86 O
. O

A O
substitution O
at O
codon O
86 O
resulted O
in O
an O
extremely O
variable O
expression O
of O
the O
disease O
in O
a O
large O
Swiss O
family O
. O

An O
extended O
homology O
search O
revealed O
a O
distant O
relationship O
of O
this O
stretch O
to O
the O
vasodilator O
- O
stimulated O
phosphoprotein O
( O
VASP O
) O
, O
which O
is O
involved O
in O
the O
maintenance O
of O
cyto O
- O
architecture O
by O
interacting O
with O
actin O
- O
like O
filaments O
. O
. O

Influence O
of O
PAX6 O
gene O
dosage O
on O
development O
: O
overexpression O
causes O
severe O
eye B
abnormalities I
. O

To O
investigate O
the O
role O
of O
gene O
dosage O
in O
more O
detail O
, O
we O
have O
generated O
yeast O
artificial O
chromosome O
transgenic O
mice O
carrying O
the O
human O
PAX6 O
locus O
. O

When O
crossed O
onto O
the O
Small O
eye O
background O
, O
the O
transgene O
rescues O
the O
mutant O
phenotype O
. O

Thus O
, O
at O
least O
five O
different O
eye O
phenotypes O
are O
associated O
with O
changes O
in O
PAX6 O
expression O
. O

Heterodimer O
formation O
and O
activity O
in O
the O
human O
enzyme O
galactose O
- O
1 O
- O
phosphate O
uridylyltransferase O
. O

One O
of O
the O
fundamental O
questions O
concerning O
expression O
and O
function O
of O
dimeric O
enzymes O
involves O
the O
impact O
of O
naturally O
occurring O
mutations O
on O
subunit O
assembly O
and O
heterodimer O
activity O
. O

Furthermore O
, O
the O
broad O
range O
of O
phenotypic O
severity O
observed O
in O
these O
patients O
raises O
the O
possibility O
that O
allelic O
combination O
, O
not O
just O
allelic O
constitution O
, O
may O
play O
some O
role O
in O
determining O
outcome O
. O

In O
the O
work O
described O
herein O
, O
we O
have O
selected O
two O
distinct O
naturally O
occurring O
null O
mutations O
of O
GALT O
, O
Q188R O
and O
R333W O
, O
and O
asked O
the O
questions O
( O
i O
) O
what O
are O
the O
impacts O
of O
these O
mutations O
on O
subunit O
assembly O
, O
and O
( O
ii O
) O
if O
heterodimers O
do O
form O
, O
are O
they O
active O
? O

To O
answer O
these O
questions O
, O
we O
have O
established O
a O
yeast O
system O
for O
the O
coexpression O
of O
epitope O
- O
tagged O
alleles O
of O
human O
GALT O
and O
investigated O
both O
the O
extent O
of O
specific O
GALT O
subunit O
interactions O
and O
the O
activity O
of O
defined O
heterodimer O
pools O
. O

We O
have O
found O
that O
both O
homodimers O
and O
heterodimers O
do O
form O
involving O
each O
of O
the O
mutant O
subunits O
tested O
and O
that O
both O
heterodimer O
pools O
retain O
substantial O
enzymatic O
activity O
. O

Cleavage O
of O
huntingtin O
by O
apopain O
, O
a O
proapoptotic O
cysteine O
protease O
, O
is O
modulated O
by O
the O
polyglutamine O
tract O
. O

Apopain O
, O
a O
human O
counterpart O
of O
the O
nematode O
cysteine O
protease O
death O
- O
gene O
product O
, O
CED O
- O
3 O
, O
has O
a O
key O
role O
in O
proteolytic O
events O
leading O
to O
apoptosis O
. O

The O
rate O
of O
cleavage O
increases O
with O
the O
length O
of O
the O
huntingtin O
polyglutamine O
tract O
, O
providing O
an O
explanation O
for O
the O
gain O
- O
of O
- O
function O
associated O
with O
CAG O
expansion O
. O

The O
5 O
' O
end O
of O
the O
BRCA1 O
gene O
lies O
within O
a O
duplicated O
region O
of O
human O
chromosome O
17q21 O
. O

To O
begin O
to O
address O
the O
hypothesis O
that O
abnormal O
regulation O
of O
the O
breast B
/ I
ovarian I
cancer I
susceptibility O
gene O
BRCA1 O
is O
a O
critical O
step O
in O
sporadic O
breast B
/ I
ovarian I
tumorigenesis I
, O
we O
have O
determined O
the O
detailed O
structure O
of O
the O
BRCA1 O
genomic O
region O
. O

We O
show O
that O
this O
region O
of O
the O
genome O
contains O
a O
tandem O
duplication O
of O
approximately O
30 O
kilobases O
, O
which O
results O
in O
two O
copies O
of O
BRCA1 O
exons O
1 O
and O
2 O
, O
of O
exons O
1 O
and O
3 O
of O
the O
adjacent O
1A1 O
- O
3B O
gene O
and O
of O
the O
previously O
reported O
295 O
base O
pair O
intergenic O
region O
. O

Sequence O
analysis O
of O
the O
duplicated O
exons O
of O
BRCA1 O
and O
1A1 O
- O
3B O
and O
flanking O
genomic O
DNA O
reveals O
maintenance O
of O
the O
intron O
- O
exon O
structure O
and O
a O
high O
degree O
of O
nucleotide O
sequence O
identity O
, O
suggesting O
that O
these O
are O
non O
- O
processed O
pseudogenes O
and O
that O
the O
duplication O
is O
a O
recent O
event O
in O
evolutionary O
terms O
. O

We O
also O
show O
that O
a O
processed O
pseudogene O
of O
the O
acidic O
ribosomal O
phosphoprotein O
P1 O
( O
ARPP1 O
) O
is O
inserted O
directly O
upstream O
of O
pseudo O
- O
BRCA1 O
exon O
1A O
. O

We O
believe O
that O
these O
findings O
could O
not O
only O
confound O
BRCA1 O
mutation O
analysis O
, O
but O
could O
have O
implications O
for O
the O
normal O
and O
abnormal O
regulation O
of O
BRCA1 O
transcription O
, O
translation O
and O
function O
. O
. O

Neither O
a O
cytogenetically O
detectable O
15q12 O
deletion O
nor O
a O
deletion O
for O
the O
D15S11 O
, O
D15S10 O
, O
and O
GABRB3 O
cosmid O
probes O
were O
found O
in O
either O
patient O
. O

The O
common O
hereditary O
forms O
of O
breast B
cancer I
have O
been O
largely O
attributed O
to O
the O
inheritance O
of O
mutations O
in O
the O
BRCA1 O
or O
BRCA2 O
genes O
. O

Twenty O
- O
three O
families O
were O
identified O
through O
two O
high O
- O
risk O
breast B
cancer I
research O
programs O
. O

Genetic O
analysis O
was O
undertaken O
to O
establish O
linkage O
between O
the O
breast B
or I
ovarian I
cancer I
cases O
and O
markers O
on O
chromosomes O
17q O
( O
BRCA1 O
) O
and O
13q O
( O
BRCA2 O
) O
. O

Mutation O
analysis O
in O
the O
BRCA1 O
and O
BRCA2 O
genes O
was O
also O
undertaken O
in O
all O
families O
. O

No O
families O
were O
attributed O
to O
BRCA2 O
. O

Five O
families O
( O
22 O
% O
) O
provided O
evidence O
against O
linkage O
to O
both O
BRCA1 O
and O
BRCA2 O
. O

No O
BRCA1 O
or O
BRCA2 O
mutations O
were O
detected O
in O
these O
five O
families O
. O

The O
BRCA1 O
or O
BRCA2 O
status O
of O
four O
families O
( O
17 O
% O
) O
could O
not O
be O
determined O
. O

The O
first O
step O
in O
the O
splicing O
of O
an O
intron O
from O
nuclear O
precursors O
of O
mRNA O
results O
in O
the O
formation O
of O
a O
lariat O
structure O
. O

A O
distinct O
intronic O
nucleotide O
sequence O
, O
known O
as O
the O
branchpoint O
region O
, O
plays O
a O
central O
role O
in O
this O
process O
. O

We O
here O
describe O
a O
point O
mutation O
in O
such O
a O
sequence O
. O

By O
performing O
in O
vitro O
expression O
of O
LCAT O
minigenes O
and O
reverse O
transcriptase O
PCR O
on O
mRNA O
isolated O
from O
leukocytes O
of O
the O
patient O
, O
this O
gene O
defect O
was O
shown O
to O
cause O
a O
null O
allele O
as O
the O
result O
of O
complete O
intron O
retention O
. O

In O
addition O
, O
our O
finding O
illustrates O
the O
importance O
of O
this O
sequence O
for O
normal O
human O
mRNA O
processing O
. O

Finally O
, O
this O
report O
provides O
a O
widely O
applicable O
strategy O
which O
ensures O
fast O
and O
effective O
screening O
for O
intronic O
defects O
that O
underlie O
differential O
gene O
expression O
. O
. O

In O
10 O
of O
these O
families O
, O
all O
the O
homozygotes O
have O
a O
137 O
- O
bp O
insertion O
in O
their O
cDNA O
caused O
by O
a O
point O
mutation O
in O
a O
sequence O
resembling O
a O
splice O
- O
donor O
site O
. O

We O
show O
that O
the O
less O
severe O
phenotype O
in O
these O
patients O
is O
caused O
by O
some O
degree O
of O
normal O
splicing O
, O
which O
occurs O
as O
an O
alternative O
product O
from O
the O
insertion O
- O
containing O
allele O
. O

The O
level O
of O
the O
137 O
- O
bp O
PCR O
product O
containing O
the O
insertion O
was O
lowest O
in O
two O
patients O
who O
showed O
a O
later O
onset O
of O
cerebellar B
ataxia I
. O

A O
further O
four O
families O
who O
do O
not O
have O
this O
insertion O
have O
been O
identified O
. O

One O
possibility O
might O
be O
that O
individuals O
who O
are O
compound O
heterozygotes O
for O
ATM O
mutations O
are O
more O
common O
than O
we O
realize O
. O
. O

Mutation O
of O
the O
VHL O
gene O
is O
associated O
exclusively O
with O
the O
development O
of O
non B
- I
papillary I
renal I
cell I
carcinomas I
. O

Chromosome O
3p O
deletion O
was O
detected O
in O
98 O
per O
cent O
of O
non O
- O
papillary B
renal I
cell I
carcinomas I
and O
in O
25 O
per O
cent O
of O
chromophobe B
renal I
cell I
carcinomas I
. O

In O
22 O
of O
the O
43 O
non O
- O
papillary B
renal I
cell I
carcinomas I
, O
abnormally O
migrating O
DNA O
bands O
were O
detected O
by O
SSCP O
and O
/ O
or O
HD O
analysis O
. O

No O
mobility O
shift O
was O
seen O
in O
any O
of O
the O
23 O
chromophobe O
renal B
cell I
carcinomas I
. O

A O
large O
fragment O
of O
emerin O
cDNA O
was O
prepared O
by O
PCR O
and O
expressed O
as O
a O
recombinant O
protein O
in O
Escherichia O
coli O
. O

Using O
this O
as O
immunogen O
, O
we O
prepared O
a O
panel O
of O
12 O
monoclonal O
antibodies O
which O
recognise O
at O
least O
four O
different O
epitopes O
on O
emerin O
in O
order O
to O
ensure O
that O
emerin O
can O
be O
distinguished O
from O
non O
- O
specific O
cross O
- O
reacting O
proteins O
. O

All O
the O
mAbs O
recognised O
a O
34 O
kDa O
protein O
in O
all O
tissues O
tested O
, O
though O
minor O
emerin O
- O
related O
bands O
were O
also O
detected O
in O
some O
tissues O
. O

Immunofluorescence O
microscopy O
showed O
that O
emerin O
is O
located O
at O
the O
nuclear O
rim O
in O
all O
tissues O
examined O
. O

Biochemical O
fractionation O
of O
brain O
and O
liver O
tissues O
showed O
that O
emerin O
was O
present O
in O
nuclei O
purified O
by O
centrifugation O
through O
65 O
% O
sucrose O
and O
was O
absent O
from O
soluble O
fractions O
( O
post O
- O
100 O
, O
000 O
g O
) O
. O

From O
these O
results O
, O
together O
with O
sequence O
and O
structural O
homologies O
between O
emerin O
, O
thymopoietins O
and O
the O
nuclear O
lamina O
- O
associated O
protein O
, O
LAP2 O
, O
we O
suggest O
that O
emerin O
will O
prove O
to O
be O
one O
member O
of O
a O
family O
of O
inner O
nuclear O
membrane O
proteins O
. O
. O

Mutation O
of O
MSH3 O
in O
endometrial B
cancer I
and O
evidence O
for O
its O
functional O
role O
in O
heteroduplex O
repair O
. O

It O
is O
therefore O
of O
interest O
to O
identify O
other O
genes O
that O
contribute O
to O
this O
instability O
. O

In O
yeast O
, O
mutations O
in O
several O
genes O
, O
including O
RTH O
and O
MSH3 O
, O
cause O
microsatellite B
instability O
. O

Thus O
, O
we O
screened O
16 O
endometrial B
carcinomas I
with O
microsatellite O
instability O
for O
alterations O
in O
FEN1 O
( O
the O
human O
homolog O
of O
RTH O
) O
and O
in O
MSH3 O
( O
refs O
12 O
- O
14 O
) O
. O

Although O
we O
found O
no O
FEN1 O
mutations O
, O
a O
frameshift O
mutation O
in O
MSH3 O
was O
observed O
in O
an O
endometrial B
carcinoma I
and O
in O
an O
endometrial B
carcinoma I
cell O
line O
. O

Extracts O
of O
the O
cell O
line O
were O
deficient O
in O
repair O
of O
DNA O
substrates O
containing O
mismatches O
or O
extra O
nucleotides O
. O

Introducing O
chromosome O
5 O
, O
encoding O
the O
MSH3 O
gene O
, O
into O
the O
mutant O
cell O
line O
increased O
the O
stability O
of O
some O
but O
not O
all O
microsatellites O
. O

Extracts O
of O
these O
cells O
repaired O
certain O
substrates O
containing O
extra O
nucleotides O
, O
but O
were O
deficient O
in O
repair O
of O
those O
containing O
mismatches O
or O
other O
extra O
nucleotides O
. O

A O
subsequent O
search O
revealed O
a O
second O
gene O
mutation O
in O
HHUA O
cells O
, O
a O
missense O
mutation O
in O
the O
MSH6 O
gene O
. O

Both O
genes O
were O
colocalized O
to O
the O
C O
- O
D O
band O
of O
mouse O
chromosome O
9 O
, O
the O
proximal O
end O
of O
q24 O
. O

1 O
of O
rat O
chromosome O
8 O
, O
and O
qa4 O
- O
qa5 O
of O
Syrian O
hamster O
chromosome O
12 O
. O

The O
regions O
in O
the O
mouse O
and O
rat O
were O
homologous O
to O
human O
chromosome O
11q O
. O

Atm O
, O
Acat1 O
, O
and O
Npat O
, O
which O
is O
a O
new O
gene O
isolated O
from O
the O
AT O
region O
, O
and O
12 O
flanking O
microsatellite O
DNA O
markers O
were O
examined O
. O

No O
recombinations O
were O
found O
among O
the O
Atm O
, O
Npat O
, O
Acat1 O
, O
and O
D9Mit6 O
loci O
, O
and O
these O
loci O
were O
mapped O
2 O
. O

0 O
cM O
distal O
to O
D9Mit99 O
and O
1 O
. O

3 O
cM O
proximal O
to O
D9Mit102 O
. O

Comparison O
of O
the O
linkage O
map O
of O
mouse O
chromosome O
9 O
( O
MMU9 O
) O
and O
that O
of O
human O
chromosome O
11 O
( O
HSA11 O
) O
indicates O
that O
there O
is O
a O
chromosomal O
rearrangement O
due O
to O
an O
inversion O
between O
Ets1 O
and O
Atm O
- O
Npat O
- O
Acat1 O
and O
that O
the O
inversion O
of O
MMU9 O
originated O
from O
the O
chromosomal O
breakage O
at O
the O
boundary O
between O
Gria4 O
and O
Atm O
- O
Npat O
- O
Acat1 O
on O
HSA11 O
. O

This O
type O
of O
inversion O
appeared O
to O
be O
conserved O
in O
the O
three O
rodent O
species O
, O
mouse O
, O
rat O
, O
and O
Syrian O
hamster O
, O
using O
additional O
comparative O
mapping O
data O
with O
the O
Rck O
gene O

RNA O
in O
situ O
hybridization O
revealed O
expression O
in O
retina O
, O
brain O
and O
the O
olfactory O
bulb O
and O
epithelium O
of O
2 O
week O
old O
mice O
. O

The O
outer O
plexiform O
layer O
disappears O
occasionally O
, O
resulting O
in O
a O
juxtaposed O
inner O
and O
outer O
nuclear O
layer O
. O

At O
the O
same O
regions O
, O
the O
outer O
segments O
of O
the O
photoreceptor O
cell O
layer O
are O
no O
longer O
present O
. O

PAX3 O
codes O
for O
a O
transcriptional O
regulator O
that O
controls O
developmental O
programs O
, O
and O
FKHR O
codes O
for O
a O
forkhead O
- O
winged O
helix O
protein O
, O
also O
a O
likely O
transcription O
factor O
. O

The O
PAX3 O
- O
FKHR O
fusion O
product O
retains O
the O
DNA O
binding O
domains O
of O
the O
PAX3 O
protein O
and O
the O
putative O
activator O
domain O
of O
the O
FKHR O
protein O
. O

The O
PAX3 O
- O
FKHR O
protein O
has O
been O
shown O
to O
function O
as O
a O
transcriptional O
activator O
. O

Using O
the O
RCAS O
retroviral O
vector O
, O
we O
have O
introduced O
the O
PAX3 O
- O
FKHR O
gene O
into O
chicken O
embryo O
fibroblasts O
. O

Expression O
of O
the O
PAX3 O
- O
FKHR O
protein O
in O
these O
cells O
leads O
to O
transformation O
the O
cells O
become O
enlarged O
, O
grow O
tightly O
packed O
and O
in O
multiple O
layers O
, O
and O
acquire O
the O
ability O
for O
anchorage O
- O
independent O
growth O
. O

This O
cellular O
transformation O
in O
vitro O
will O
facilitate O
studies O
on O
the O
mechanism O
of O
PAX3 O
- O
FKHR O
- O
induced O
oncogenesis B
. O
. O

X O
- O
chromosome O
inactivation O
in O
mammals O
is O
regarded O
as O
an O
essentially O
random O
process O
, O
but O
the O
resulting O
somatic O
- O
cell O
mosaicism O
creates O
the O
opportunity O
for O
cell O
selection O
. O

In O
order O
to O
test O
this O
possibility O
we O
have O
analyzed O
four O
heterozygotes O
for O
class O
I O
G6PD O
mutations O
two O
with O
G6PD O
Portici B
( O
1178G O
- O
- O
> O
A O
) O
and O
two O
with O
G6PD O
Bari O
( O
1187C O
- O
- O
> O
T O
) O
. O

We O
found O
that O
in O
fractionated O
blood O
cell O
types O
( O
including O
erythroid O
, O
myeloid O
, O
and O
lymphoid O
cell O
lineages O
) O
there O
was O
a O
significant O
excess O
of O
G6PD O
- O
normal O
cells O
. O

The O
significant O
concordance O
that O
we O
have O
observed O
in O
the O
degree O
of O
imbalance O
in O
the O
different O
blood O
- O
cell O
lineages O
indicates O
that O
a O
selective O
mechanism O
is O
likely O
to O
operate O
at O
the O
level O
of O
pluripotent O
blood O
stem O
cells O
. O

Using O
statistical O
models O
specifically O
designed O
to O
study O
single O
- O
sperm O
segregation O
data O
, O
we O
find O
no O
evidence O
of O
meiotic O
segregation O
distortion O
. O

The O
upper O
limit O
of O
the O
two O
- O
sided O
95 O
% O
confidence O
interval O
for O
the O
estimate O
of O
the O
common O
segregation O
probability O
for O
the O
three O
donors O
is O
at O
or O
below O
. O

515 O
for O
all O
models O
considered O
, O
and O
no O
statistically O
significant O
difference O
from O
. O

5 O
is O
detected O
in O
any O
of O
the O
models O
. O

Multiple O
chromosomes O
have O
been O
found O
as O
the O
translocation O
partners O
of O
chromosome O
12 O
but O
3q27 O
- O
q28 O
is O
preferentially O
involved O
. O

In O
previous O
studies O
, O
it O
has O
been O
shown O
that O
the O
high O
mobility O
group O
( O
HMG O
) O
protein O
gene O
HMGIC O
at O
12q15 O
is O
consistently O
rearranged O
as O
a O
consequence O
of O
these O
translocations O
. O

In O
Northern O
blot O
analysis O
, O
an O
mRNA O
of O
over O
10 O
kb O
was O
detected O
by O
these O
ectopic O
sequences O
in O
a O
variety O
of O
human O
tissues O
but O
not O
in O
brain O
and O
peripheral O
blood O
leukocytes O
. O

Upon O
partial O
cDNA O
cloning O
, O
features O
of O
the O
genetic O
organization O
of O
LPP O
were O
established O
. O

The O
gene O
was O
found O
to O
span O
a O
genomic O
region O
of O
over O
400 O
kb O
. O

Nucleotide O
sequence O
analysis O
of O
a O
composite O
cDNA O
of O
LPP O
revealed O
an O
open O
reading O
frame O
of O
1836 O
nucleotides O
encoding O
a O
proline O
- O
rich O
protein O
containing O
a O
leucine O
- O
zipper O
motif O
in O
its O
amino O
- O
terminal O
region O
and O
three O
LIM O
domains O
in O
its O
carboxy O
- O
terminal O
region O
. O

The O
LPP O
- O
encoded O
protein O
should O
be O
classified O
as O
a O
novel O
member O
of O
the O
group O
3 O
proteins O
of O
the O
LIM O
protein O
gene O
family O
. O

Two O
alternative O
HMGIC O
/ O
LPP O
hybrid O
transcripts O
have O
been O
detected O
; O
the O
difference O
between O
them O
is O
mainly O
the O
presence O
of O
either O
two O
or O
three O
LIM O
domains O
in O
the O
predicted O
HMGI O
- O
C O
/ O
LPP O
fusion O
proteins O
. O
. O

By O
1 O
year O
, O
these O
mice O
have O
no O
behavioral B
abnormalities I
and O
morphometric O
analysis O
at O
6 O
( O
one O
animal O
) O
and O
9 O
( O
two O
animals O
) O
months O
age O
revealed O
no O
changes O
. O

In O
contrast O
to O
that O
seen O
in O
humans O
, O
the O
CAG O
repeat O
in O
these O
mice O
was O
remarkably O
stable O
in O
97 O
meioses O
. O

This O
suggests O
that O
genomic O
sequences O
may O
play O
a O
critical O
role O
in O
influencing O
repeat O
instability O
. O
. O

G6PD O
activity O
was O
detected O
in O
samples O
obtained O
from O
biopsies O
on O
the O
quadriceps O
muscle O
of O
seven O
males O
and O
one O
female O
. O

The O
type O
of O
genetic O
variant O
was O
determined O
by O
molecular O
analysis O
of O
DNA O
, O
extracted O
from O
blood O
samples O
. O

All O
variants O
showed O
the O
enzyme O
defect O
in O
muscle O
. O

A O
statistically O
significant O
relationship O
was O
found O
in O
the O
activity O
of O
G6PD O
between O
erythrocytes O
and O
muscle O
of O
the O
male O
subjects O
( O
r O
= O
0 O
. O
968 O
; O
p O
= O
0 O
. O
00008 O
) O
. O

The O
equation O
for O
the O
best O
fit O
line O
was O
Y O
= O
0 O
. O

390X O
+ O
0 O
. O

198 O
198 O
. O

The O
results O
suggest O
that O
, O
for O
a O
given O
variant O
, O
the O
extent O
of O
the O
enzyme O
defect O
in O
muscle O
may O
be O
determined O
, O
using O
this O
equation O
, O
from O
the O
G6PD O
activity O
of O
erythrocytes O

Three O
different O
vector O
systems O
have O
been O
examined O
. O

This O
treatment O
is O
transient O
and O
cannot O
be O
effectively O
re O
- O
administered O
due O
to O
the O
presence O
of O
neutralizing O
antibodies O
directed O
against O
the O
recombinant O
adenoviral O
vector O
. O

Exon O
- O
intron O
structure O
of O
the O
human O
neuronal O
nicotinic O
acetylcholine O
receptor O
alpha O
4 O
subunit O
( O
CHRNA4 O
) O
. O

We O
have O
determined O
the O
genomic O
organization O
of O
CHRNA4 O
, O
which O
consists O
of O
six O
exons O
distributed O
over O
approximately O
17 O
kb O
of O
genomic O
DNA O
. O

The O
nucleotide O
sequence O
obtained O
from O
the O
genomic O
regions O
adjacent O
to O
the O
exon O
boundaries O
enabled O
us O
to O
develop O
a O
set O
of O
primer O
pairs O
for O
PCR O
amplification O
of O
the O
complete O
coding O
region O
. O

Ashkenazi O
Jewish O
population O
frequencies O
for O
common O
mutations O
in O
BRCA1 O
and O
BRCA2 O
. O

Over O
85 O
distinct O
BRCA1 O
mutations O
and O
a O
growing O
list O
of O
BRCA2 O
mutations O
have O
been O
identified O
, O
with O
the O
majority O
resulting O
in O
protein O
truncation O
. O

A O
specific O
BRCA1 O
mutation O
, O
185delAG O
, O
has O
a O
reported O
increased O
carrier O
frequency O
of O
approximately O
0 O
. O

9 O
% O
in O
the O
Ashkenazi O
Jewish O
population O
, O
but O
is O
also O
found O
in O
rare O
non O
- O
Jewish O
patients O
with O
a O
different O
haplotype O
. O

We O
have O
conducted O
a O
large O
- O
scale O
population O
study O
to O
investigate O
the O
prevalence O
of O
specific O
BRCA1 O
and O
BRCA2 O
mutations O
in O
Ashkenazi O
Jewish O
individuals O
who O
were O
unselected O
for O
breast B
cancer I
. O

BRCA1 O
mutation O
screening O
on O
approximately O
3 O
, O
000 O
Ashkenazi O
Jewish O
samples O
determined O
a O
carrier O
frequency O
of O
1 O
. O

09 O
% O
for O
the O
185delAG O
mutation O
and O
0 O
. O

13 O
% O
for O
the O
5382insC O
mutation O
. O

BRCA2 O
analysis O
on O
3 O
, O
085 O
individuals O
from O
the O
same O
population O
showed O
a O
carrier O
frequency O
of O
1 O
. O

52 O
% O
for O
the O
6174delT O
mutation O
. O

Dual O
roles O
of O
ATM O
in O
the O
cellular O
response O
to O
radiation O
and O
in O
cell O
growth O
control O
. O

To O
elucidate O
the O
functions O
of O
ATM O
, O
we O
disrupted O
the O
mouse O
ATM O
gene O
through O
homologous O
recombination O
in O
mice O
. O

In O
addition O
, O
ATM O
- O
/ O
- O
mouse O
thymocytes O
are O
more O
resistant O
to O
apoptosis O
induced O
by O
gamma O
- O
irradiation O
than O
normal O
thymocytes O
. O

ATM O
- O
/ O
- O
fibroblasts O
are O
inefficient O
in O
G1 O
to O
S O
- O
phase O
progression O
following O
serum O
stimulation O
and O
senesce O
after O
only O
a O
few O
passages O
in O
culture O
. O

They O
have O
an O
increased O
constitutive O
level O
of O
p21CP1 O
/ O
WAF1 O
. O

The O
ATM O
protein O
is O
therefore O
critical O
both O
for O
cellular O
responses O
to O
ionizing O
radiation O
and O
for O
normal O
cell O
- O
cycle O
progression O
. O

To O
help O
clarify O
the O
physiological O
roles O
of O
the O
ATM O
protein O
, O
we O
disrupted O
the O
ATM O
gene O
in O
mice O
through O
homologous O
recombination O
. O

The O
homozygous O
mutant O
( O
ATM O
- O
/ O
- O
) O
mice O
are O
viable O
, O
growth B
- I
retarded I
, O
and O
infertile B
. O

The O
infertility B
of O
ATM O
- O
/ O
- O
mice O
results O
from O
meiotic O
failure O
. O

Meiosis O
is O
arrested O
at O
the O
zygotene O
/ O
pachytene O
stage O
of O
prophase O
I O
as O
a O
result O
of O
abnormal O
chromosomal O
synapsis O
and O
subsequent O
chromosome O
fragmentation O
. O

The O
cerebella O
of O
ATM O
- O
/ O
- O
mice O
appear O
normal O
by O
histologic O
examination O
at O
3 O
to O
4 O
months O
and O
the O
mice O
have O
no O
gross O
behavioral B
abnormalities I
. O

These O
findings O
indicate O
that O
the O
ATM O
gene O
product O
plays O
an O
essential O
role O
in O
a O
diverse O
group O
of O
cellular O
processes O
, O
including O
meiosis O
, O
the O
normal O
growth O
of O
somatic O
tissues O
, O
immune O
development O
, O
and O
tumor B
suppression O
. O
. O

Cloning O
and O
characterization O
of O
human O
very O
- O
long O
- O
chain O
acyl O
- O
CoA O
dehydrogenase O
cDNA O
, O
chromosomal O
assignment O
of O
the O
gene O
and O
identification O
in O
four O
patients O
of O
nine O
different O
mutations O
within O
the O
VLCAD O
gene O
. O

Very O
- O
long O
- O
chain O
acyl O
- O
CoA O
dehydrogenase O
( O
VLCAD O
) O
is O
one O
of O
four O
straight O
- O
chain O
acyl O
- O
CoA O
dehydrogenase O
( O
ACD O
) O
enzymes O
, O
which O
are O
all O
nuclear O
encoded O
mitochondrial O
flavoproteins O
catalyzing O
the O
initial O
step O
in O
fatty O
acid O
beta O
- O
oxidation O
. O

We O
have O
used O
the O
very O
fast O
, O
Rapid O
Amplification O
of O
cDNA O
Ends O
( O
RACE O
) O
based O
strategy O
to O
obtain O
the O
sequence O
of O
cDNAs O
encoding O
human O
VLCAD O
from O
placenta O
and O
fibroblasts O
. O

Alignment O
of O
the O
predicted O
amino O
acid O
sequence O
of O
human O
VLCAD O
with O
those O
of O
the O
other O
human O
ACD O
enzymes O
revealed O
extensive O
sequence O
homology O
. O

Moreover O
, O
human O
VLCAD O
and O
human O
acyl O
- O
CoA O
oxidase O
showed O
extensive O
sequence O
homology O
corroborating O
the O
notion O
that O
these O
genes O
are O
evolutionarily O
related O
. O

Southern O
blot O
analysis O
of O
genomic O
DNA O
from O
hybrid O
cell O
lines O
was O
used O
to O
localize O
the O
VLCAD O
gene O
to O
human O
chromosome O
17p11 O
. O

2 O
- O
p11 O
. O

13105 O
. O

Using O
Northern O
and O
Western O
blot O
analysis O
to O
investigate O
the O
tissue O
specific O
distribution O
of O
VLCAD O
mRNA O
and O
protein O
in O
several O
human O
tissues O
we O
showed O
that O
VLCAD O
is O
most O
abundant O
in O
heart O
and O
skeletal O
muscle O
. O

Western O
blot O
analysis O
of O
patient O
fibroblasts O
showed O
that O
the O
identified O
mutations O
result O
in O
severely O
reduced O
amounts O
of O
VLCAD O
protein O
. O

A O
defect O
at O
the O
5 O
splice O
donor O
site O
of O
intron O
15 O
of O
the O
C6 O
gene O
explains O
the O
low O
molecular O
weight O
of O
the O
C6 O
protein O
and O
is O
probably O
responsible O
for O
its O
low O
expressed O
concentration O
. O

The O
C7 O
defect O
is O
more O
enigmatic O
the O
protein O
is O
of O
normal O
molecular O
weight O
, O
low O
circulating O
concentration O
, O
and O
altered O
isoelectric O
point O
. O

An O
Arg O
> O
Ser O
codon O
substitution O
in O
exon O
11 O
is O
the O
only O
molecular O
alteration O
within O
the O
mature O
C7 O
protein O
. O

These O
defects O
are O
associated O
with O
a O
characteristic O
set O
of O
polymorphic O
DNA O
markers O
in O
the O
C6 O
/ O
C7 O
region O
, O
forming O
a O
distinct O
haplotype O
. O

In O
contrast O
, O
where O
the O
C7 O
genes O
are O
both O
defective O
( O
but O
still O
partially O
functional O
) O
, O
there O
may O
be O
a O
profound O
deficit O
of O
circulating O
C7 O
because O
there O
is O
ample O
C6 O
to O
produce O
C56 O
and O
consume O
the O
already O
small O
amount O
of O
C7 O
. O

Each O
molecular O
defect O
has O
also O
been O
found O
in O
isolation O
and O
has O
the O
expected O
effect O
. O
. O

We O
used O
exon O
- O
specific O
PCR O
/ O
single O
- O
strand O
conformation O
polymorphism O
analysis O
as O
a O
screening O
step O
for O
mutations O
. O

Subsequent O
direct O
sequencing O
of O
the O
target O
exons O
identified O
homozygous O
mutations O
in O
exon O
16 O
of O
case O
1 O
and O
in O
exon O
15 O
of O
case O
2 O
. O

The O
mutation O
of O
case O
1 O
was O
a O
homozygous O
T O
to O
A O
transversion O
at O
nucleotide O
2250 O
, O
the O
third O
nucleotide O
of O
the O
codon O
TGT O
for O
Cys728 O
, O
leading O
to O
a O
stop O
codon O
TGA O
( O
C728X O
) O
. O

In O
case O
2 O
, O
a O
homozygous O
2 O
- O
bp O
deletion O
( O
2137delTG O
/ O
2138delGT O
/ O
2139delTG O
) O
caused O
a O
frameshift O
, O
generating O
a O
premature O
termination O
codon O
4 O
to O
6 O
nucleotides O
downstream O
. O

Family O
study O
in O
case O
1 O
confirmed O
the O
genetic O
nature O
of O
the O
defect O
. O

Somatic O
alterations O
of O
the O
DPC4 O
gene O
in O
human O
colorectal B
cancers I
in O
vivo O
. O

BACKGROUND O
& O
AIMS O
The O
chromosome O
region O
18q21 O
has O
been O
shown O
to O
be O
frequently O
deleted O
in O
colorectal B
cancers I
, O
and O
such O
frequent O
allelic O
loss O
is O
a O
hallmark O
of O
the O
presence O
of O
a O
tumor O
- O
suppressor O
gene O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
determine O
if O
it O
might O
also O
be O
altered O
in O
colorectal B
cancers I
. O

METHODS O
Mutation O
analyses O
of O
the O
DPC4 O
gene O
were O
performed O
on O
complementary O
DNA O
samples O
from O
31 O
primary O
colorectal B
cancer I
specimens O
using O
a O
combination O
of O
polymerase O
chain O
reaction O
, O
single O
- O
strand O
conformation O
polymorphism O
, O
and O
DNA O
sequencing O
. O

RESULTS O
Four O
missense O
mutations O
producing O
amino O
acid O
substitutions O
and O
a O
somatic O
12 O
- O
base O
pair O
deletion O
in O
the O
coding O
region O
of O
the O
DPC4 O
gene O
were O
detected O
in O
the O
31 O
cancers B
( O
16 O
% O
; O
5 O
of O
31 O
) O
. O

CONCLUSIONS O
The O
DPC4 O
gene O
may O
play O
a O
role O
as O
a O
tumor O
- O
suppressor O
gene O
in O
a O
fraction O
of O
colorectal B
cancers I
; O
however O
, O
while O
allelic O
loss O
at O
18q21 O
is O
very O
often O
seen O
in O
colorectal B
cancers I
, O
only O
a O
minority O
show O
DPC4 O
mutations O
, O
suggesting O
that O
there O
might O
be O
another O
tumor O
- O
suppressor O
gene O
in O
this O
chromosome O
region O
. O
. O

Atm O
- O
deficient O
fibroblasts O
grow O
poorly O
in O
culture O
and O
display O
a O
high O
level O
of O
double O
- O
stranded O
chromosome O
breaks O
. O

Atm O
- O
deficient O
thymocytes O
undergo O
spontaneous O
apoptosis O
in O
vitro O
significantly O
more O
than O
controls O
. O

Furthermore O
, O
we O
demonstrate O
that O
the O
Atm O
protein O
exists O
as O
two O
discrete O
molecular O
species O
, O
and O
that O
loss O
of O
one O
or O
of O
both O
of O
these O
can O
lead O
to O
the O
development O
of O
the O
disease O
. O
. O

The O
DCC O
protein O
and O
prognosis O
in O
colorectal B
cancer I
. O

BACKGROUND O
Allelic O
loss O
of O
chromosome O
18q O
predicts O
a O
poor O
outcome O
in O
patients O
with O
stage O
II O
colorectal B
cancer I
. O

Although O
the O
specific O
gene O
inactivated O
by O
this O
allelic O
loss O
has O
not O
been O
elucidated O
, O
the O
DCC O
( O
deleted O
in O
colorectal B
cancer I
) O
gene O
is O
a O
candidate O
. O

We O
investigated O
whether O
the O
expression O
of O
the O
DCC O
protein O
in O
tumor B
cells O
is O
a O
prognostic O
marker O
in O
colorectal B
carcinoma I
. O

The O
Cox O
proportional O
- O
hazards O
model O
was O
used O
to O
adjust O
for O
covariates O
including O
age O
, O
sex O
, O
tumor B
site O
, O
degree O
of O
tumor B
differentiation O
, O
and O
use O
of O
adjuvant O
therapy O
. O

In O
patients O
with O
stage O
II O
disease O
whose O
tumors B
expressed O
DCC O
, O
the O
five O
- O
year O
survival O
rate O
was O
94 O
. O

6 O
percent O
( O
P O
< O
0 O
. O
001 O
) O
. O

3 O
percent O
and O
33 O
. O

2 O
percent O
( O
P O
= O
0 O
. O
03 O
) O
. O

These O
findings O
may O
thus O
have O
therapeutic O
implications O
in O
this O
group O
of O
patients O

Transporter O
- O
facilitated O
uptake O
of O
serotonin O
( O
5 O
- O
hydroxytryptamine O
or O
5 O
- O
HT O
) O
has O
been O
implicated O
in O
anxiety B
in O
humans O
and O
animal O
models O
and O
is O
the O
site O
of O
action O
of O
widely O
used O
uptake O
- O
inhibiting O
antidepressant O
and O
antianxiety O
drugs O
. O

Human O
5 O
- O
HT O
transporter O
( O
5 O
- O
HTT O
) O
gene O
transcription O
is O
modulated O
by O
a O
common O
polymorphism O
in O
its O
upstream O
regulatory O
region O
. O

The O
short O
variant O
of O
the O
polymorphism O
reduces O
the O
transcriptional O
efficiency O
of O
the O
5 O
- O
HTT O
gene O
promoter O
, O
resulting O
in O
decreased O
5 O
- O
HTT O
expression O
and O
5 O
- O
HT O
uptake O
in O
lymphoblasts O
. O

Reduced O
incorporation O
of O
inorganic O
sulfate O
into O
macromolecules O
was O
found O
in O
all O
three O
. O

Each O
of O
the O
three O
patients O
was O
found O
to O
be O
heterozygous O
for O
a O
c862t O
transition O
predicting O
a O
R279W O
substitution O
in O
the O
third O
extracellular O
loop O
of O
DTDST O
. O

Also O
the O
delta O
c418 O
allele O
was O
underrepresented O
in O
the O
cDNA O
, O
in O
accordance O
with O
previous O
observations O
that O
premature O
stop O
codons O
reduce O
mRNA O
levels O
. O

By O
analysis O
of O
these O
compiled O
mutation O
data O
, O
we O
demonstrated O
clustering O
of O
WASP O
mutations O
within O
the O
four O
most O
N O
- O
terminal O
exons O
of O
the O
gene O
and O
also O
identified O
several O
sites O
within O
this O
region O
as O
hotspots O
for O
WASP O
mutation O
. O

These O
characteristics O
were O
observed O
, O
however O
, O
in O
both O
severe O
and O
mild O
cases O
of O
the O
disease O
. O

Complete O
genomic O
sequence O
and O
analysis O
of O
117 O
kb O
of O
human O
DNA O
containing O
the O
gene O
BRCA1 O
. O

Over O
100 O
distinct O
disease O
- O
associated O
mutations O
have O
been O
identified O
in O
the O
breast B
- I
ovarian I
cancer I
susceptibility O
gene O
BRCA1 O
. O

Loss O
of O
the O
wild O
- O
type O
allele O
in O
> O
90 O
% O
of O
tumors B
from O
patients O
with O
inherited O
BRCA1 O
mutations O
indicates O
tumor B
suppressive O
function O
. O

The O
low O
incidence O
of O
somatic O
mutations O
suggests O
that O
BRCA1 O
inactivation O
in O
sporadic O
tumors B
occurs O
by O
alternative O
mechanisms O
, O
such O
as O
interstitial O
chromosomal O
deletion O
or O
reduced O
transcription O
. O

To O
identify O
possible O
features O
of O
the O
BRCA1 O
genomic O
region O
that O
may O
contribute O
to O
chromosomal B
instability I
as O
well O
as O
potential O
transcriptional O
regulatory O
elements O
, O
a O
117 O
, O
143 O
- O
bp O
DNA O
sequence O
encompassing O
BRCA1 O
was O
obtained O
by O
random O
sequencing O
of O
four O
cosmids O
identified O
from O
a O
human O
chromosome O
17 O
specific O
library O
. O

The O
24 O
exons O
of O
BRCA1 O
span O
an O
81 O
- O
kb O
region O
that O
has O
an O
unusually O
high O
density O
of O
Alu O
repetitive O
DNA O
( O
41 O
. O
5 O
% O
) O
, O
but O
relatively O
low O
density O
( O
4 O
. O
8 O
% O
) O
of O
other O
repetitive O
sequences O
. O

BRCA1 O
intron O
lengths O
range O
in O
size O
from O
403 O
bp O
to O
9 O
. O

2 O
kb O
and O
contain O
the O
intragenic O
microsatellite O
markers O
D17S1323 O
, O
D17S1322 O
, O
and O
D17S855 O
, O
which O
localize O
to O
introns O
12 O
, O
19 O
, O
and O
20 O
, O
respectively O
. O

In O
addition O
to O
BRCA1 O
, O
the O
contig O
contains O
two O
complete O
genes O
Rho7 O
, O
a O
member O
of O
the O
rho O
family O
of O
GTP O
binding O
proteins O
, O
and O
VAT1 O
, O
an O
abundant O
membrane O
protein O
of O
cholinergic O
synaptic O
vesicles O
. O

Partial O
sequences O
of O
the O
1A1 O
- O
3B O
B O
- O
box O
protein O
pseudogene O
and O
IFP O
35 O
, O
an O
interferon O
induced O
leucine O
zipper O
protein O
, O
reside O
within O
the O
contig O
. O

An O
L21 O
ribosomal O
protein O
pseudogene O
is O
embedded O
in O
BRCA1 O
intron O
13 O
. O

The O
order O
of O
genes O
on O
the O
chromosome O
is O
centromere O
- O
1FP O
35 O
- O
VAT1 O
- O
Rho7 O
- O
BRCA1 O
- O
1A1 O
- O
3B O
- O
telomere O

Identification O
of O
a O
RING O
protein O
that O
can O
interact O
in O
vivo O
with O
the O
BRCA1 O
gene O
product O
. O

Here O
we O
describe O
a O
novel O
protein O
that O
interacts O
in O
vivo O
with O
the O
N O
- O
terminal O
region O
of O
BRCA1 O
. O

This O
BRCA1 O
- O
associated O
RING O
domain O
( O
BARD1 O
) O
protein O
contains O
an O
N O
- O
terminal O
RING O
motif O
, O
three O
tandem O
ankyrin O
repeats O
, O
and O
a O
C O
- O
terminal O
sequence O
with O
significant O
homology O
to O
the O
phylogenetically O
conserved O
BRCT O
domains O
that O
lie O
near O
the O
C O
terminus O
of O
BRCA1 O
. O

The O
BARD1 O
/ O
BRCA1 O
interaction O
is O
disrupted O
by O
BRCA1 O
missense O
mutations O
that O
segregate O
with O
breast B
cancer I
susceptibility O
, O
indicating O
that O
BARD1 O
may O
be O
involved O
in O
mediating O
tumour B
suppression O
by O
BRCA1 O
. O
. O

Detection O
of O
heterozygous O
mutations O
in O
BRCA1 O
using O
high O
density O
oligonucleotide O
arrays O
and O
two O
- O
colour O
fluorescence O
analysis O
. O

The O
ability O
to O
scan O
a O
large O
gene O
rapidly O
and O
accurately O
for O
all O
possible O
heterozygous O
mutations O
in O
large O
numbers O
of O
patient O
samples O
will O
be O
critical O
for O
the O
future O
of O
medicine O
. O

We O
have O
designed O
high O
- O
density O
arrays O
consisting O
of O
over O
96 O
, O
600 O
oligonucleotides O
20 O
- O
nucleotides O
( O
nt O
) O
in O
length O
to O
screen O
for O
a O
wide O
range O
of O
heterozygous O
mutations O
in O
the O
3 O
. O

Reference O
and O
test O
samples O
were O
co O
- O
hybridized O
to O
these O
arrays O
and O
differences O
in O
hybridization O
patterns O
quantitated O
by O
two O
- O
colour O
analysis O
. O

Fourteen O
of O
fifteen O
patient O
samples O
with O
known O
mutations O
were O
accurately O
diagnosed O
, O
and O
no O
false O
positive O
mutations O
were O
identified O
in O
20 O
control O
samples O
. O

Eight O
single O
nucleotide O
polymorphisms O
were O
also O
readily O
detected O
. O

DNA O
chip O
- O
based O
assays O
may O
provide O
a O
valuable O
new O
technology O
for O
high O
- O
throughput O
cost O
- O
efficient O
detection O
of O
genetic O
alterations O
. O

The O
possibility O
of O
the O
latter O
cosegregating O
as O
a O
separate O
autosomal O
dominant O
gene O
can O
not O
be O
ruled O
out O
. O

Meiotic O
recombinations O
detected O
in O
affected O
individuals O
placed O
the O
locus O
telomeric O
of O
D1S215 O
, O
thus O
narrowing O
the O
HRPT2 O
region O
from O
> O
60 O
to O
approximately O
34 O
centimorgans O
. O

The O
losses O
invariably O
involved O
the O
wild O
type O
allele O
derived O
from O
the O
unaffected O
parent O
, O
suggesting O
the O
inactivation O
of O
a O
tumor O
suppressor O
gene O
in O
this O
region O

Independent O
origin O
of O
single O
and O
double O
mutations O
in O
the O
human O
glucose O
6 O
- O
phosphate O
dehydrogenase O
gene O
. O

The O
vast O
majority O
of O
both O
polymorphic O
and O
sporadic O
G6PD O
variants O
are O
due O
to O
single O
missense O
mutations O
. O

In O
the O
four O
polymorphic O
variants O
that O
have O
two O
point O
mutations O
, O
one O
of O
the O
mutations O
is O
always O
376 O
A O
- O
- O
> O
G O
( O
126 O
Asn O
- O
- O
> O
Asp O
) O
, O
which O
on O
its O
own O
gives O
rise O
to O
the O
nondeficient O
polymorphic O
variant O
, O
G6PD O
A O
. O

This O
is O
the O
same O
mutation O
as O
previously O
found O
in O
association O
with O
the O
mutation O
of O
G6PD O
A O
in O
the O
double O
mutant O
, O
G6PD O
Santamaria O
. O

G6PD O
Santamaria O
might O
have O
been O
produced O
by O
recombination O
between O
G6PD O
A O
and O
G6PD O
Malaga O
; O
however O
haplotype O
analysis O
, O
including O
the O
use O
of O
a O
new O
silent O
polymorphism O
, O
suggests O
that O
the O
same O
542 O
A O
- O
- O
> O
T O
mutation O
has O
taken O
place O
independently O
in O
a O
G6PD O
B O
gene O
to O
give O
G6PD O
Malaga O
and O
in O
a O
G6PD O
A O
gene O
to O
give O
G6PD O
Santamaria O
. O

These O
findings O
help O
to O
outline O
the O
relationship O
and O
evolution O
of O
mutations O
in O
the O
human O
G6PD O
locus O
. O
. O

BRCA1 O
R841W O
: O
a O
strong O
candidate O
for O
a O
common O
mutation O
with O
moderate O
phenotype O
. O

BRCA1 O
mutations O
cause O
increased O
risk O
for O
breast B
and I
ovarian I
cancer I
, O
frequently O
of O
early O
onset O
. O

Many O
different O
mutations O
occur O
in O
BRCA1 O
, O
including O
several O
examples O
of O
recurrent O
mutations O
, O
each O
of O
which O
accounts O
for O
a O
significant O
number O
of O
families O
with O
heritable O
cancer B
predisposition O
. O

These O
common O
mutations O
have O
an O
etiological O
role O
in O
many O
breast B
and I
ovarian I
cancer I
cases O
and O
provide O
the O
opportunity O
to O
examine O
genotype O
- O
phenotype O
correlations O
and O
genotype O
- O
environment O
interactions O
in O
individuals O
with O
the O
identical O
BRCA1 O
lesion O
. O

These O
are O
consecutive O
, O
population O
- O
based O
cases O
not O
selected O
for O
age O
or O
family O
history O
. O

The O
age O
of O
cancer B
onset O
was O
not O
always O
distinct O
from O
typical O
sporadic O
cases O
. O

Testing O
of O
a O
sample O
of O
413 O
unrelated O
individuals O
to O
examine O
the O
hypothesis O
that O
R841W O
might O
be O
a O
rare O
polymorphism O
detected O
one O
additional O
instance O
in O
a O
woman O
with O
breast B
cancer I
diagnosed O
at O
age O
77 O
years O
, O
and O
cancer B
in O
one O
parent O
. O

R841W O
is O
likely O
to O
be O
an O
etiologically O
significant O
lesion O
with O
involvement O
in O
close O
to O
1 O
% O
( O
95 O
% O
confidence O
interval O
of O
0 O
- O
1 O
. O
7 O
% O
) O
of O
all O
breast B
and I
ovarian I
cancers I
in O
this O
population O
. O

This O
mutation O
, O
103C O
- O
- O
> O
T O
, O
results O
in O
a O
stop O
codon O
at O
position O
35 O
of O
the O
ATM O
protein O
. O

In O
keeping O
with O
the O
nature O
of O
this O
mutation O
, O
various O
antibodies O
directed O
against O
the O
ATM O
protein O
failed O
to O
defect O
this O
protein O
in O
patient O
cells O
. O

A O
rapid O
carrier O
detection O
assay O
detected O
this O
mutation O
in O
three O
out O
of O
488 O
ATM O
alleles O
of O
Jewish O
Moroccan O
or O
Tunisian O
origin O
. O

Nine O
( O
17 O
% O
) O
of O
the O
patients O
had O
a O
family O
history O
of O
breast B
and I
/ I
or I
ovarian I
cancer I
in O
at O
least O
one O
first O
- O
degree O
relative O
. O

A O
further O
seven O
( O
13 O
% O
) O
of O
the O
patients O
reported O
breast B
/ I
ovarian I
cancer I
in O
at O
least O
one O
second O
- O
degree O
relative O
and O
in O
no O
first O
- O
degree O
relatives O
. O

No O
germ O
- O
line O
BRCA1 O
mutations O
were O
found O
. O

The O
Duarte O
biochemical O
phenotype O
has O
a O
molecular O
genotype O
of O
N314D O
/ O
N314D O
. O

The O
characteristic O
Duarte O
isoform O
is O
also O
associated O
with O
a O
variant O
called O
the O
" O
Los O
Angeles O
( O
LA O
) O
phenotype O
, O
" O
which O
has O
increased O
GALT O
enzyme O
activity O
. O

We O
evaluated O
GALT O
enzyme O
activity O
and O
screened O
the O
GALT O
genes O
of O
145 O
patients O
with O
one O
or O
more O
N314D O
- O
containing O
alleles O
. O

We O
found O
seven O
with O
the O
LA O
biochemical O
phenotype O
, O
and O
all O
had O
a O
1721C O
- O
- O
> O
T O
transition O
in O
exon O
7 O
in O
cis O
with O
the O
N314D O
missense O
mutation O
. O

The O
1721C O
- O
- O
> O
T O
transition O
is O
a O
neutral O
polymorphism O
for O
leucine O
at O
amino O
acid O
218 O
( O
L218L O
) O
. O

In O
pedigree O
analyses O
, O
this O
1721C O
- O
- O
> O
T O
transition O
segregated O
with O
the O
LA O
phenotype O
of O
increased O
GALT O
activity O
in O
three O
different O
biochemical O
phenotypes O
( O
LA O
/ O
N O
, O
LA O
/ O
G O
, O
and O
LA O
/ O
D O
) O
. O

To O
determine O
the O
mechanism O
for O
increased O
activity O
of O
the O
LA O
variant O
, O
we O
compared O
GALT O
mRNA O
, O
protein O
abundance O
, O
and O
enzyme O
thermal O
stability O
in O
lymphoblast O
cell O
lines O
of O
D O
and O
LA O
phenotypes O
with O
comparable O
genotypes O
. O

GALT O
protein O
abundance O
was O
increased O
in O
LA O
compared O
to O
D O
alleles O
, O
but O
mRNA O
was O
similar O
among O
all O
genotypes O
. O

When O
LA O
/ O
D O
and O
D O
/ O
D O
GALT O
biochemical O
phenotypes O
were O
compared O
to O
N O
/ O
N O
GALT O
phenotypes O
, O
both O
had O
50 O
% O
, O
as O
compared O
to O
21 O
% O
, O
reduction O
in O
GALT O
activity O
in O
the O
wild O
type O
( O
N O
/ O
N O
) O
after O
exposure O
at O
identical O
initial O
enzyme O
activity O
to O
50 O
degrees O
C O
for O
15 O
min O
. O

A O
favorable O
codon O
bias O
for O
the O
mutated O
codon O
with O
consequently O
increased O
translation O
rates O
is O
postulated O
as O
the O
mechanism O
. O
. O

The O
TSG101 O
tumor B
susceptibility O
gene O
is O
located O
in O
chromosome O
11 O
band O
p15 O
and O
is O
mutated O
in O
human O
breast B
cancer I
. O

Here O
, O
we O
report O
that O
the O
human O
homolog O
, O
TSG101 O
, O
which O
we O
isolated O
and O
mapped O
to O
chromosome O
11 O
, O
bands O
15 O
. O

1 O
- O
15 O
1 O
- O
15 O
. O

2 O
, O
a O
region O
proposed O
to O
contain O
tumor O
suppressor O
gene O
( O
s O
) O
, O
is O
mutated O
at O
high O
frequency O
in O
human O
breast B
cancer I
. O

In O
7 O
of O
15 O
uncultured O
primary O
human O
breast B
carcinomas I
, O
intragenic O
deletions O
were O
shown O
in O
TSG101 O
genomic O
DNA O
and O
transcripts O
by O
gel O
and O
sequence O
analysis O
, O
and O
mutations O
affecting O
two O
TSG101 O
alleles O
were O
identified O
in O
four O
of O
these O
cancers B
. O

No O
TSG101 O
defects O
were O
found O
in O
matched O
normal O
breast O
tissue O
from O
the O
breast B
cancer I
patients O
. O

These O
findings O
strongly O
implicate O
TSG101 O
mutations O
in O
human O
breast B
cancer I

Moderate O
intergenerational O
and O
somatic O
instability O
of O
a O
55 O
- O
CTG O
repeat O
in O
transgenic O
mice O
. O

The O
( O
CTG O
) O
n O
repeat O
is O
polymorphic O
and O
varies O
in O
size O
between O
5 O
and O
37 O
repeats O
in O
unaffected O
individuals O
whereas O
in O
affected O
patients O
there O
are O
between O
50 O
and O
4 O
, O
000 O
CTGs O
. O

The O
size O
of O
the O
( O
CTG O
) O
n O
repeat O
, O
which O
increases O
through O
generations O
, O
generally O
correlates O
with O
clinical O
severity O
and O
age O
of O
onset O
. O

The O
instability O
of O
the O
CTG O
repeat O
appears O
to O
depend O
on O
its O
size O
as O
well O
as O
on O
the O
sex O
of O
the O
transmitting O
parent O
. O

The O
molecular O
mechanisms O
of O
triplet O
instability O
remain O
elusive O
. O

To O
investigate O
the O
role O
of O
genomic O
sequences O
in O
instability O
, O
we O
produced O
transgenic O
mice O
containing O
a O
45 O
- O
kb O
genomic O
segment O
with O
a O
55 O
- O
CTG O
repeat O
cloned O
from O
a O
mildly O
affected O
patient O
. O

In O
contrast O
to O
other O
mouse O
models O
containing O
CAG O
repeats O
within O
cDNAs O
, O
these O
mice O
showed O
both O
intergenerational O
and O
somatic O
repeat O
instability O
. O
. O

Programmed O
cell O
death O
( O
or O
apoptosis O
) O
is O
a O
physiological O
process O
essential O
to O
the O
normal O
development O
and O
homeostatic O
maintenance O
of O
the O
immune O
system O
. O

In O
all O
three O
siblings O
, O
we O
demonstrated O
the O
presence O
of O
anergic O
CD3 O
+ O
CD4 O
- O
CD8 O
- O
( O
double O
negative O
, O
[ O
DN O
] O
) O
T O
cells O
; O
moreover O
, O
a O
chronic O
lymphocyte O
activation O
was O
found O
, O
as O
demonstrated O
by O
the O
presence O
of O
high O
levels O
of O
HLA O
- O
DR O
expression O
on O
peripheral O
CD3 O
+ O
cells O
and O
by O
the O
presence O
of O
high O
levels O
of O
serum O
activation O
markers O
such O
as O
soluble O
interleukin O
- O
2 O
receptor O
( O
slL O
- O
2R O
) O
and O
soluble O
CD30 O
( O
sCD30 O
) O
. O
. O

The O
ATM O
protein O
is O
a O
single O
, O
high O
- O
molecular O
weight O
protein O
predominantly O
confined O
to O
the O
nucleus O
of O
human O
fibroblasts O
, O
but O
is O
present O
in O
both O
nuclear O
and O
microsomal O
fractions O
from O
human O
lymphoblast O
cells O
and O
peripheral O
blood O
lymphocytes O
. O

ATM O
protein O
levels O
and O
localization O
remain O
constant O
throughout O
all O
stages O
of O
the O
cell O
cycle O
. O

Exposure O
of O
normal O
human O
cells O
to O
gamma O
- O
irradiation O
and O
the O
radiomimetic O
drug O
neocarzinostatin O
had O
no O
effect O
on O
ATM O
protein O
levels O
, O
in O
contrast O
to O
a O
noted O
rise O
in O
p53 O
levels O
over O
the O
same O
time O
interval O
. O

These O
findings O
are O
consistent O
with O
a O
role O
for O
the O
ATM O
protein O
in O
ensuring O
the O
fidelity O
of O
DNA O
repair O
and O
cell O
cycle O
regulation O
following O
genome O
damage O
. O
. O

Type O
III O
collagen O
is O
crucial O
for O
collagen O
I O
fibrillogenesis O
and O
for O
normal O
cardiovascular O
development O
. O

Type O
III O
collagen O
is O
a O
fibrillar O
forming O
collagen O
comprising O
three O
alpha1 O
( O
III O
) O
chains O
and O
is O
expressed O
in O
early O
embryos O
and O
throughout O
embryogenesis O
. O

In O
the O
adult O
, O
type O
III O
collagen O
is O
a O
major O
component O
of O
the O
extracellular O
matrix O
in O
a O
variety O
of O
internal O
organs O
and O
skin O
. O

To O
directly O
study O
the O
role O
of O
Col3a1 O
in O
development O
and O
disease O
, O
we O
have O
inactivated O
the O
Col3a1 O
gene O
in O
embryonic O
stem O
cells O
by O
homologous O
recombination O
. O

The O
mutated O
allele O
was O
transmitted O
through O
the O
mouse O
germ O
line O
and O
homozygous O
mutant O
animals O
were O
derived O
from O
heterozygous O
intercrosses O
. O

About O
10 O
% O
of O
the O
homozygous O
mutant O
animals O
survived O
to O
adulthood O
but O
have O
a O
much O
shorter O
life O
span O
compared O
with O
wild O
- O
type O
mice O
. O

Ultrastructural O
analysis O
of O
tissues O
from O
mutant O
mice O
revealed O
that O
type O
III O
collagen O
is O
essential O
for O
normal O
collagen O
I O
fibrillogenesis O
in O
the O
cardiovascular O
system O
and O
other O
organs O
. O
. O

The O
mutation O
, O
which O
creates O
a O
second O
AluI O
restriction O
site O
, O
results O
in O
a O
nonsense O
mutation O
in O
PLP O
. O

Common O
BRCA1 O
variants O
and O
susceptibility O
to O
breast B
and I
ovarian I
cancer I
in O
the O
general O
population O
. O

Most O
multiple O
case O
families O
of O
young O
onset O
breast B
cancer I
and O
ovarian B
cancer I
are O
thought O
to O
be O
due O
to O
highly O
penetrant O
mutations O
in O
the O
predisposing O
genes O
BRCA1 O
and O
BRCA2 O
. O

However O
, O
these O
mutations O
are O
uncommon O
in O
the O
population O
and O
they O
probably O
account O
for O
only O
a O
few O
percent O
of O
all O
breast B
cancer I
incidence O
. O

A O
much O
larger O
fraction O
of O
breast B
cancer I
might O
, O
in O
principle O
, O
be O
due O
to O
common O
variants O
which O
confer O
more O
modest O
individual O
risks O
. O

There O
are O
several O
common O
polymorphisms O
in O
the O
BRCA1 O
gene O
which O
generate O
amino O
acid O
substitutions O
. O

We O
have O
examined O
the O
frequency O
of O
four O
of O
these O
polymorphisms O
Gln356Arg O
, O
Pro871Leu O
, O
Glu1038Gly O
and O
Ser1613Gly O
in O
large O
series O
of O
breast B
and I
ovarian I
cancer I
cases O
and O
matched O
controls O
. O

Due O
to O
strong O
linkage O
disequilibrium O
, O
these O
four O
sites O
generate O
only O
three O
haplotypes O
with O
a O
frequency O
> O
1 O
. O

3 O
% O
. O

The O
most O
common O
haplotypes O
, O
defined O
by O
the O
alleles O
Gln356Pro871Glu1038Ser1613 O
and O
Gln356Leu871Gly1038Gly1613 O
, O
have O
frequencies O
of O
0 O
. O

57 O
and O
0 O
. O

32 O
respectively O
, O
and O
these O
frequencies O
do O
not O
differ O
significantly O
between O
patient O
and O
control O
groups O
. O

Thus O
the O
most O
common O
polymorphisms O
of O
the O
BRCA1 O
gene O
do O
not O
make O
a O
significant O
contribution O
to O
breast B
or I
ovarian I
cancer I
risk O
. O

However O
, O
our O
data O
suggest O
that O
the O
Arg356 O
allele O
may O
have O
a O
different O
genotype O
distribution O
in O
breast B
cancer I
patients O
from O
that O
in O
controls O
( O
Arg356 O
homozygotes O
are O
more O
frequent O
in O
the O
control O
groups O
, O
P O
= O
0 O
. O
01 O
) O
, O
indicating O
that O
it O
may O
be O
protective O
against O
breast B
cancer I
. O

If O
this O
finding O
can O
be O
confirmed O
, O
it O
may O
provide O
an O
insight O
into O
the O
structural O
features O
of O
the O
BRCA1 O
protein O
that O
are O
important O
for O
its O
function O
. O

Kniest O
, O
his O
patient O
, O
the O
molecular O
defect O
. O

Molecular O
analysis O
of O
the O
patients O
DNA O
showed O
a O
single O
base O
( O
G O
) O
deletion O
involving O
the O
GT O
dinucleotide O
at O
the O
start O
of O
intron O
18 O
destroying O
a O
splice O
site O
of O
the O
COL2A1 O
gene O
. O

We O
determined O
48 O
amino O
acid O
residues O
from O
five O
peptides O
from O
the O
homogeneous O
monomer O
of O
homogentisate O
1 O
, O
2 O
- O
dioxygenase O
( O
HGO O
; O
E O
. O
C O
. O
1 O
. O
13 O
. O
11 O
. O
15 O
) O
of O
mouse O
liver O
. O

After O
digestion O
with O
trypsin O
, O
peptides O
were O
separated O
by O
reversed O
phase O
chromatography O
and O
amino O
acid O
sequenced O
. O

The O
deduced O
codon O
sequence O
of O
three O
peptides O
was O
used O
to O
derive O
degenerated O
oligomeres O
. O

By O
combining O
these O
oligos O
, O
we O
were O
able O
to O
amplify O
fragments O
from O
100 O
to O
300 O
bases O
( O
b O
) O
from O
mouse O
liver O
cDNA O
by O
polymerase O
chain O
reaction O
after O
reverse O
transcription O
( O
RT O
- O
PCR O
) O
. O

A O
fragment O
of O
200 O
b O
was O
cloned O
and O
used O
as O
a O
probe O
to O
screen O
a O
mouse O
liver O
cDNA O
library O
. O

One O
clone O
from O
this O
library O
contained O
the O
complete O
cDNA O
- O
insert O
for O
HGO O
as O
determined O
by O
sequencing O
. O

The O
cDNA O
encodes O
for O
a O
protein O
of O
50 O
kDa O
, O
as O
predicted O
. O

The O
cDNA O
of O
mouse O
HGO O
has O
an O
overall O
identity O
of O
41 O
% O
to O
the O
corresponding O
gene O
hmgA O
from O
Aspergillus B
. O

Sequence O
similarities O
to O
human O
expressed O
sequence O
tags O
( O
EST O
) O
clones O
ranged O
from O
70 O
% O
to O
20 O
% O
. O

The O
positions O
of O
122 O
conserved O
amino O
acids O
could O
be O
determined O
by O
multiple O
sequence O
alignment O
. O

We O
identified O
one O
first O
intron O
of O
928 O
b O
in O
the O
mouse O
gene O
. O

The O
gene O
for O
HGO O
seems O
to O
be O
expressed O
in O
various O
tissues O
, O
as O
shown O
by O
RT O
- O
PCR O
on O
different O
cDNAs O
. O

FISH O
experiments O
with O
the O
whole O
murine O
cDNA O
as O
probe O
clearly O
revealed O
signals O
at O
the O
human O
chromosomal O
band O
3q13 O
. O

3 O
- O
q21 O
. O

PTEN O
, O
a O
putative O
protein O
tyrosine O
phosphatase O
gene O
mutated O
in O
human O
brain B
, I
breast I
, I
and I
prostate I
cancer I
. O

Mapping O
of O
homozygous O
deletions O
on O
human O
chromosome O
10q23 O
has O
led O
to O
the O
isolation O
of O
a O
candidate O
tumor O
suppressor O
gene O
, O
PTEN O
, O
that O
appears O
to O
be O
mutated O
at O
considerable O
frequency O
in O
human O
cancers B
. O

In O
preliminary O
screens O
, O
mutations O
of O
PTEN O
were O
detected O
in O
31 O
% O
( O
13 O
/ O
42 O
) O
of O
glioblastoma B
cell O
lines O
and O
xenografts O
, O
100 O
% O
( O
4 O
/ O
4 O
) O
of O
prostate B
cancer I
cell O
lines O
, O
6 O
% O
( O
4 O
/ O
65 O
) O
of O
breast B
cancer I
cell O
lines O
and O
xenografts O
, O
and O
17 O
% O
( O
3 O
/ O
18 O
) O
of O
primary O
glioblastomas B
. O

The O
predicted O
PTEN O
product O
has O
a O
protein O
tyrosine O
phosphatase O
domain O
and O
extensive O
homology O
to O
tensin O
, O
a O
protein O
that O
interacts O
with O
actin O
filaments O
at O
focal O
adhesions O
. O

We O
studied O
the O
clinical O
and O
radiological O
features O
in O
81 O
patients O
from O
the O
literature O
and O
5 O
own O
patients O
trying O
to O
identify O
distinct O
subgroups O
. O

Within O
this O
latter O
group O
, O
there O
are O
differences O
in O
age O
of O
manifestation O
, O
clinical O
course O
and O
pattern O
of O
bone O
changes O
. O

A O
tentative O
clinico O
- O
radiological O
classification O
can O
be O
useful O
for O
the O
characterization O
of O
patients O
and O
the O
development O
of O
genotype O
- O
phenotype O
correlations O
. O
. O

A O
clinical O
overview O
of O
WT1 O
gene O
mutations O
. O

Six O
years O
on O
, O
we O
review O
100 O
reports O
of O
intragenic O
WT1 O
mutations O
and O
examine O
the O
accompanying O
clinical O
phenotypes O
. O

Here O
, O
we O
report O
that O
a O
mutation O
predicting O
the O
substitution O
of O
Gly O
230 O
by O
glutamic O
acid O
( O
G230E O
) O
between O
segments O
D3 O
and O
D4 O
dramatically O
alters O
the O
pore O
properties O
of O
a O
recombinant O
human O
muscle O
Cl O
- O
channel O
( O
hCIC O
- O
1 O
) O
expressed O
in O
a O
mammalian O
cell O
line O
( O
tsA201 O
) O
. O

The O
G230E O
mutation O
causes O
substantial O
changes O
in O
anion O
and O
cation O
selectivity O
as O
well O
as O
a O
fundamental O
change O
in O
rectification O
of O
the O
current O
- O
voltage O
relationship O
. O

Whereas O
wild O
- O
type O
channels O
are O
characterized O
by O
pronounced O
inward O
rectification O
and O
a O
Cl O
> O
thiocyanate O
> O
Br O
> O
NO O
( O
3 O
) O
> O
I O
> O
CH O
( O
3 O
) O
SO O
( O
3 O
) O
selectivity O
, O
G230E O
exhibits O
outward O
rectification O
at O
positive O
potentials O
and O
a O
thiocyanate O
> O
NO O
( O
3 O
) O
> O
I O
> O
Br O
> O
Cl O
> O
CH O
( O
3 O
) O
SO O
( O
3 O
) O
selectivity O
. O

Furthermore O
, O
the O
cation O
- O
to O
- O
anion O
permeability O
ratio O
of O
the O
mutant O
is O
much O
greater O
than O
that O
of O
the O
wild O
- O
type O
channel O
. O

Voltage O
- O
dependent O
blocks O
by O
intracellular O
and O
extracellular O
iodide O
help O
to O
distinguish O
two O
distinct O
ion O
binding O
sites O
within O
the O
hClC O
- O
1 O
conduction O
pathway O
. O

Both O
binding O
sites O
are O
preserved O
in O
the O
mutant O
but O
have O
decreased O
affinities O
for O
iodide O
. O

These O
findings O
suggest O
that O
Gly O
230 O
is O
critical O
for O
normal O
ion O
conductance O
in O
hClC O
- O
1 O
and O
that O
this O
residue O
resides O
within O
the O
channel O
pore O
. O
. O

Mutations O
were O
detected O
in O
90 O
% O
of O
the O
cases O
. O

Three O
mutation O
detection O
techniques O
were O
used O
to O
determine O
if O
one O
method O
was O
superior O
for O
this O
gene O
. O

The O
protein O
truncation O
test O
( O
PTT O
) O
was O
used O
on O
RT O
- O
PCR O
products O
, O
SSCP O
on O
genomic O
PCR O
amplifications O
, O
and O
chemical O
cleavage O
of O
mismatch O
on O
both O
RT O
- O
PCR O
and O
genomic O
amplifications O
. O

For O
RT O
- O
PCR O
products O
, O
only O
the O
translated O
portion O
of O
the O
gene O
was O
screened O
. O

On O
genomic O
products O
exons O
1 O
to O
13 O
( O
including O
740 O
bp O
of O
the O
3 O
untranslated O
sequence O
and O
all O
intron O
/ O
exon O
boundaries O
) O
were O
screened O
, O
as O
was O
a O
neuroretina O
specific O
enhancer O
in O
intron O
4 O
. O

Ten O
of O
the O
possible O
12 O
mutations O
in O
the O
five O
familial O
cases O
and O
five O
of O
the O
sporadic O
patients O
were O
found O
, O
all O
of O
which O
conformed O
to O
a O
functional O
outcome O
of O
haploinsufficiency O
. O

Five O
were O
splice O
site O
mutations O
( O
one O
in O
the O
donor O
site O
of O
intron O
4 O
, O
two O
in O
the O
donor O
site O
of O
intron O
6 O
, O
one O
in O
each O
of O
the O
acceptor O
sites O
of O
introns O
8 O
and O
9 O
) O
and O
five O
were O
nonsense O
mutations O
in O
exons O
8 O
, O
9 O
, O
10 O
, O
11 O
, O
and O
12 O
. O

SSCP O
analysis O
of O
individually O
amplified O
exons O
, O
with O
which O
nine O
of O
the O
10 O
mutations O
were O
seen O
, O
was O
the O
most O
useful O
detection O
method O
for O
PAX6 O
. O
. O

The O
human O
complement O
C9 O
gene O
: O
identification O
of O
two O
mutations O
causing O
deficiency O
and O
revision O
of O
the O
gene O
structure O
. O

The O
ninth O
component O
of O
human O
complement O
( O
C9 O
) O
is O
the O
last O
of O
the O
terminal O
complement O
components O
creating O
the O
membrane O
attack O
complex O
. O

C9 O
is O
a O
single O
- O
chain O
serum O
protein O
that O
is O
encoded O
by O
a O
gene O
located O
on O
chromosome O
5p O
. O

One O
mutation O
, O
a O
C O
to O
A O
exchange O
, O
was O
detected O
in O
exon O
2 O
at O
cDNA O
position O
166 O
, O
the O
other O
, O
a O
C O
to O
T O
exchange O
, O
was O
located O
in O
exon O
4 O
( O
cDNA O
position O
464 O
) O
. O

Therefore O
, O
these O
mutations O
are O
sufficient O
to O
explain O
the O
complete O
deficiency O
of O
both O
the O
probands O
studied O
. O

DNA O
sequencing O
of O
the O
exon O
- O
intron O
junctions O
revealed O
a O
number O
of O
revisions O
regarding O
the O
boundaries O
between O
exons O
4 O
, O
5 O
, O
and O
6 O
as O
well O
as O
between O
exons O
10 O
and O
11 O
. O

No O
additional O
introns O
were O
detected O
in O
exons O
6 O
and O
10 O
. O

Furthermore O
, O
DNA O
marker O
studies O
were O
conducted O
using O
known O
polymorphisms O
of O
the O
C6 O
, O
C7 O
, O
and O
C9 O
genes O
, O
confirming O
the O
linkage O
of O
the O
observed O
C9 O
mutations O
with O
defined O
haplotypes O
. O
. O

BRCA1 O
mutations O
in O
women O
attending O
clinics O
that O
evaluate O
the O
risk O
of O
breast B
cancer I
. O

BACKGROUND O
To O
define O
the O
incidence O
of O
BRCA1 O
mutations O
among O
patients O
seen O
in O
clinics O
that O
evaluate O
the O
risk O
of O
breast B
cancer I
, O
we O
analyzed O
DNA O
samples O
from O
women O
seen O
in O
this O
setting O
and O
constructed O
probability O
tables O
to O
provide O
estimates O
of O
the O
likelihood O
of O
finding O
a O
BRCA1 O
mutation O
in O
individual O
families O
. O

METHODS O
Clinical O
information O
, O
family O
histories O
, O
and O
blood O
for O
DNA O
analysis O
were O
obtained O
from O
263 O
women O
with O
breast B
cancer I
. O

Conformation O
- O
sensitive O
gel O
electrophoresis O
and O
DNA O
sequencing O
were O
used O
to O
identify O
BRCA1 O
mutations O
. O

RESULTS O
BRCA1 O
mutations O
were O
identified O
in O
16 O
percent O
of O
women O
with O
a O
family O
history O
of O
breast B
cancer I
. O

Only O
7 O
percent O
of O
women O
from O
families O
with O
a O
history O
of O
breast B
cancer I
but O
not O
ovarian B
cancer I
had O
BRCA1 O
mutations O
. O

The O
rates O
were O
higher O
among O
women O
from O
families O
with O
a O
history O
of O
both O
breast B
and I
ovarian I
cancer I
. O

Among O
family O
members O
, O
an O
average O
age O
of O
less O
than O
55 O
years O
at O
the O
diagnosis O
of O
breast B
cancer I
, O
the O
presence O
of O
ovarian B
cancer I
, O
the O
presence O
of O
breast B
and I
ovarian I
cancer I
in O
the O
same O
woman O
, O
and O
Ashkenazi O
Jewish O
ancestry O
were O
all O
associated O
with O
an O
increased O
risk O
of O
detecting O
a O
BRCA1 O
mutation O
. O

No O
association O
was O
found O
between O
the O
presence O
of O
bilateral O
breast B
cancer I
or O
the O
number O
of O
breast B
cancers I
in O
a O
family O
and O
the O
detection O
of O
a O
BRCA1 O
mutation O
, O
or O
between O
the O
position O
of O
the O
mutation O
in O
the O
BRCA1 O
gene O
and O
the O
presence O
of O
ovarian B
cancer I
in O
a O
family O
. O

CONCLUSIONS O
Among O
women O
with O
breast B
cancer I
and O
a O
family O
history O
of O
the O
disease O
, O
the O
percentage O
with O
BRCA1 O
coding O
- O
region O
mutations O
is O
less O
than O
the O
45 O
percent O
predicted O
by O
genetic O
- O
linkage O
analysis O
. O

These O
results O
suggest O
that O
even O
in O
a O
referral O
clinic O
specializing O
in O
screening O
women O
from O
high O
- O
risk O
families O
, O
the O
majority O
of O
tests O
for O
BRCA1 O
mutations O
will O
be O
negative O
and O
therefore O
uninformative O
. O
. O

The O
ARP O
gene O
encodes O
a O
highly O
conserved O
arginine O
- O
rich O
protein O
from O
chromosomal O
band O
3p21 O
. O

1 O
1 O
. O

A O
group O
of O
patients O
with O
long O
- O
surviving O
mismatched O
kidney O
allografts O
were O
investigated O
for O
complement O
function O
using O
haemolytic O
assays O
in O
agarose O
gels O
. O

One O
patient O
was O
found O
to O
have O
no O
alternative O
pathway O
activity O
but O
a O
low O
normal O
classical O
pathway O
. O

Surprisingly O
, O
investigation O
revealed O
that O
the O
patients O
complement O
was O
normal O
for O
all O
components O
except O
C9 O
, O
which O
was O
functionally O
absent O
. O

Serological O
analysis O
by O
ELISA O
revealed O
that O
he O
has O
trace O
concentrations O
of O
a O
non O
- O
functional O
C9 O
molecule O
. O

Western O
blot O
analysis O
was O
not O
sufficiently O
sensitive O
to O
permit O
detection O
of O
this O
molecule O
. O

Screening O
for O
ESR O
mutations O
in O
breast B
and I
ovarian I
cancer I
patients O
. O

In O
the O
present O
study O
, O
leukocyte O
DNA O
from O
143 O
patients O
with O
familial O
clustering O
of O
breast B
and I
/ I
or I
ovarian I
cancer I
and O
tumour O
DNA O
from O
96 O
breast B
carcinomas I
were O
screened O
for O
base O
mutations O
in O
the O
estrogen O
receptor O
gene O
( O
ESR O
) O
. O

Three O
patients O
with O
a O
family O
history O
of O
cancer B
were O
carrying O
a O
Gly160Cys O
germline O
substitution O
. O

This O
alteration O
was O
also O
detected O
in O
eight O
( O
four O
females O
and O
four O
males O
) O
of O
729 O
controls O
( O
366 O
female O
, O
363 O
males O
) O
, O
indicating O
that O
the O
substitution O
probably O
represents O
a O
polymorphism O
. O

However O
, O
in O
the O
229 O
female O
controls O
in O
whom O
family O
history O
of O
cancer B
was O
known O
, O
one O
of O
two O
who O
had O
a O
sister O
with O
breast B
cancer I
was O
carrying O
the O
variant O
allele O
. O

Hence O
, O
a O
possible O
clinical O
significance O
of O
the O
glycine O
into O
cysteine O
cannot O
be O
completely O
ruled O
out O
and O
should O
be O
further O
investigated O
. O

Exon O
PCR O
and O
sequencing O
revealed O
a O
heterozygous O
point O
mutation O
at O
the O
3 O
splice O
acceptor O
site O
of O
intron O
1 O
in O
one O
Irish B
family O
. O

In O
the O
other O
Irish B
family O
, O
exons O
7 O
and O
8 O
failed O
to O
amplify O
and O
they O
were O
shown O
to O
be O
deleted O
. O

Marker O
haplotype O
studies O
of O
the O
C6 O
and O
C7 O
gene O
region O
and O
Southern O
blots O
show O
that O
the O
Irish B
family O
with O
the O
splice O
defect O
also O
segregate O
for O
the O
deletion O
, O
which O
is O
not O
easily O
detected O
in O
heterozygotes O
. O

However O
, O
one O
individual O
is O
heterozygous O
for O
markers O
at O
adjacent O
C6 O
loci O
, O
showing O
that O
there O
has O
been O
an O
intergenic O
recombination O
and O
suggesting O
that O
the O
deficiency O
mutation O
is O
of O
appreciable O
antiquity O
. O
. O

The O
most O
common O
variant O
of O
GALT B
, O
the O
Duarte O
variant O
, O
occurs O
as O
two O
types O
, O
Duarte O
- O
1 O
( O
D O
- O
1 O
) O
and O
Duarte O
- O
2 O
( O
D O
- O
2 O
) O
, O
both O
of O
which O
carry O
the O
sequence O
change O
N314D O
. O

D O
- O
1 O
increases O
, O
whereas O
D O
- O
2 O
decreases O
GALT O
activity O
. O

Q188R O
accounted O
for O
60 O
% O
, O
K285N O
accounted O
for O
28 O
% O
of O
these O
alleles O
. O

On O
all O
D O
- O
2 O
alleles O
N314D O
occurred O
in O
cis O
with O
two O
intronic O
sequence O
changes O
, O
on O
the O
D O
- O
1 O
alleles O
in O
cis O
with O
a O
neutral O
mutation O
in O
exon O
7 O
. O

ATM O
is O
a O
member O
of O
the O
phosphatidylinositol O
- O
3 O
- O
kinase O
superfamily O
, O
some O
of O
which O
are O
protein O
kinases O
and O
appear O
to O
have O
important O
roles O
in O
cell O
cycle O
control O
and O
radiation O
signal O
transduction O
. O

In O
this O
report O
, O
we O
demonstrate O
that O
in O
addition O
to O
functional O
alterations O
these O
translocations O
are O
associated O
with O
fusion O
product O
overexpression O
. O

Furthermore O
, O
PAX3 O
- O
FKHR O
and O
PAX7 O
- O
FKHR O
overexpression O
occurs O
by O
distinct O
mechanisms O
. O

Transcription O
of O
PAX3 O
- O
FKHR O
is O
increased O
relative O
to O
wild O
- O
type O
PAX3 O
by O
a O
copy O
number O
- O
independent O
process O
. O

In O
contrast O
, O
PAX7 O
- O
FKHR O
overexpression O
results O
from O
fusion O
gene O
amplification O
. O

We O
postulate O
that O
these O
overexpression O
mechanisms O
ensure O
a O
critical O
level O
of O
gene O
product O
for O
the O
oncogenic O
effects O
of O
these O
fusions O
. O
. O

The O
two O
genes O
are O
believed O
to O
interact O
in O
a O
number O
of O
pathways O
, O
including O
regulation O
of O
DNA O
damage O
- O
induced O
cell O
- O
cycle O
checkpoints O
, O
apoptosis O
and O
radiation O
sensitivity O
, O
and O
cellular O
proliferation O
. O

Atm O
- O
null O
mice O
, O
as O
well O
as O
those O
null O
for O
p53 O
, O
develop O
mainly O
T B
- I
cell I
lymphomas I
, O
supporting O
the O
view O
that O
these O
genes O
have O
similar O
roles O
in O
thymocyte O
development O
. O

To O
study O
the O
interactions O
of O
these O
two O
genes O
on O
an O
organismal O
level O
, O
we O
bred O
mice O
heterozygous O
for O
null O
alleles O
of O
both O
atm O
and O
p53 O
to O
produce O
all O
genotypic O
combinations O
. O

Mice O
doubly O
null O
for O
atm O
and O
p53 O
exhibited O
a O
dramatic O
acceleration O
of O
tumour B
formation O
relative O
to O
singly O
null O
mice O
, O
indicating O
that O
both O
genes O
collaborate O
in O
a O
significant O
manner O
to O
prevent O
tumorigenesis B
. O

With O
respect O
to O
their O
roles O
in O
apoptosis O
, O
loss O
of O
atm O
rendered O
thymocytes O
only O
partly O
resistant O
to O
irradiation O
- O
induced O
apoptosis O
, O
whereas O
additional O
loss O
of O
p53 O
engendered O
complete O
resistance O
. O

This O
implies O
that O
the O
irradiation O
- O
induced O
atm O
and O
p53 O
apoptotic O
pathways O
are O
not O
completely O
congruent O
. O

3 O
( O
refs O
1 O
- O
3 O
) O
. O

Previous O
work O
from O
our O
laboratory O
demonstrated O
that O
a O
DNase O
l O
- O
hypersensitive O
site O
located O
adjacent O
to O
the O
repeats O
on O
the O
wild O
- O
type O
allele O
is O
eliminated O
by O
repeat O
expansion O
, O
indicating O
that O
large O
CTG O
- O
repeat O
arrays O
may O
be O
associated O
with O
a O
local O
chromatin O
environment O
that O
represses O
gene O
expression O
. O

Here O
we O
report O
that O
the O
hypersensitive O
site O
contains O
an O
enhancer O
element O
that O
regulates O
transcription O
of O
the O
adjacent O
DMAHP O
homeobox O
gene O
. O

Allele O
- O
specific O
analysis O
of O
DMAHP O
expression O
showed O
that O
steady O
- O
state O
transcript O
levels O
from O
the O
expanded O
allele O
were O
greatly O
reduced O
in O
comparison O
to O
those O
from O
the O
wild O
- O
type O
allele O
. O

Mutations O
have O
been O
found O
throughout O
the O
gene O
; O
however O
, O
these O
genetic O
alterations O
do O
not O
appear O
to O
be O
homogeneously O
distributed O
. O

In O
particular O
, O
a O
significant O
proportion O
of O
disease O
- O
causing O
mutations O
results O
in O
the O
premature O
termination O
of O
protein O
synthesis O
, O
and O
the O
majority O
of O
these O
mutations O
occur O
as O
C O
- O
- O
> O
T O
transitions O
at O
CpG O
dinucleotides O
( O
CpGs O
) O
. O

Such O
recurrent O
CpG O
mutations O
, O
including O
those O
found O
in O
RB1 O
, O
are O
likely O
the O
result O
of O
the O
deamination O
of O
5 O
- O
methylcytosine O
within O
these O
CpGs O
. O

In O
the O
present O
study O
, O
we O
used O
the O
sodiumbisulfite O
conversion O
method O
to O
detect O
cytosine O
methylation O
in O
representative O
exons O
of O
RB1 O
. O

We O
analyzed O
DNA O
from O
a O
variety O
of O
tissues O
and O
specifically O
targeted O
CGA O
codons O
in O
RB1 O
, O
where O
recurrent O
premature O
termination O
mutations O
have O
been O
reported O
. O

We O
found O
that O
DNA O
methylation O
within O
RB1 O
exons O
8 O
, O
14 O
, O
25 O
, O
and O
27 O
appeared O
to O
be O
restricted O
to O
CpGs O
, O
including O
six O
CGA O
codons O
. O

Other O
codons O
containing O
methylated O
cytosines O
have O
not O
been O
reported O
to O
be O
mutated O
. O

Therefore O
, O
disease O
- O
causing O
mutations O
at O
CpGs O
in O
RB1 O
appear O
to O
be O
determined O
by O
several O
factors O
, O
including O
the O
constitutive O
presence O
of O
DNA O
methylation O
at O
cytosines O
within O
CpGs O
, O
the O
specific O
codon O
within O
which O
the O
methylated O
cytosine O
is O
located O
, O
and O
the O
particular O
region O
of O
the O
gene O
within O
which O
that O
codon O
resides O
. O
. O

We O
have O
therefore O
assessed O
the O
effect O
of O
the O
VHL O
gene O
product O
on O
VEGF O
expression O
. O

wt O
- O
VHL O
protein O
inhibited O
VEGF O
promoter O
activity O
in O
a O
dose O
- O
dependent O
manner O
up O
to O
5 O
- O
to O
10 O
- O
fold O
. O

Deletion O
analysis O
defined O
a O
144 O
- O
bp O
region O
of O
the O
VEGF O
promoter O
necessary O
for O
VHL O
repression O
. O

This O
VHL O
- O
responsive O
element O
is O
GC O
rich O
and O
specifically O
binds O
the O
transcription O
factor O
Sp1 O
in O
crude O
nuclear O
extracts O
. O

In O
Drosophila O
cells O
, O
cotransfected O
VHL O
represses O
Sp1 O
- O
mediated O
activation O
but O
not O
basal O
activity O
of O
the O
VEGF O
promoter O
. O

We O
next O
demonstrated O
in O
coimmunoprecipitates O
that O
VHL O
and O
Sp1 O
were O
part O
of O
the O
same O
complex O
and O
, O
by O
using O
a O
glutathione O
- O
S O
- O
transferase O
- O
VHL O
fusion O
protein O
and O
purified O
Sp1 O
, O
that O
VHL O
and O
Sp1 O
directly O
interact O
. O

We O
identified O
three O
missense O
mutations O
( O
I66M O
, O
G270D O
, O
L618S O
) O
and O
one O
exon O
- O
6 O
skipping O
( O
535 O
- O
573del O
) O
. O

Two O
of O
the O
patients O
had O
only O
the O
I66M O
mutant O
mRNA O
, O
and O
one O
only O
the O
G27OD O
mutant O
mRNA O
. O

The O
fourth O
patient O
carried O
a O
compound O
heterozygous O
mutation O
of O
535 O
- O
573del O
and O
L618S O
. O

To O
determine O
the O
enzymatic O
activities O
produced O
by O
these O
mutations O
, O
we O
constructed O
mutated O
GALC O
cDNAs O
and O
expressed O
them O
in O
COS O
- O
1 O
cells O
. O

The O
I66M O
mutation O
in O
the O
wild O
- O
type O
GALC B
cDNA O
( O
I289 O
) O
had O
normal O
activity O
, O
but O
when O
this O
mutation O
and O
the O
V289 O
polymorphism O
were O
introduced O
into O
the O
same O
allele O
, O
it O
had O
decreased O
activity O
. O

Thus O
, O
the O
combination O
of O
a O
unique O
mutation O
and O
polymorphism O
causes O
conformational O
change O
in O
the O
GALC O
enzyme O
, O
resulting O
in O
low O
enzymatic O
activity O
. O

